Boris Bagdasarian, MD
Hematology/Oncology · Glendale
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
- Since medical school
- 33 years
- Graduated 1993
Offices
1 location · Los Angeles Hematology-Oncology Medical Group · 51 clinicians in this group
Hospitals listed: 058421 · Glendale Adventist Medical Center · Keck Hospital of USC · USC Verdugo Hills Hospital. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Bagdasarian’s office at (818) 409-0105 to ask if they take your plan before you enroll.
Hospitals they work in
3 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Glendale Adventist Medical CenterGlendale, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Adventist Health, which runs 28 hospitals in 3 statesPatients rate it 3 of 5 · 69% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Pressure ulcer rate: 0.08 (0 to 0.57) · 9,330 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.073, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.277, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.085, Oct 2024 – Sep 2025
- Keck Hospital of USCLos Angeles, CAAcute Care Hospital · Voluntary non-profit - Other · No emergency departmentPart of University of Southern California, which runs 4 hospitalsHome of USC Norris Comprehensive Cancer Center, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 82% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — CMS Medicare PSI 90: Patient safety and adverse events composite: 0.79 (0.6 to 0.97), Jul 2022 – Jun 2024Better than the national rate — Postoperative respiratory failure rate: 5.33 (2.15 to 8.51) · 2,872 cases, Jul 2022 – Jun 2024Better than the national rate — Postoperative sepsis rate: 2.25 (0.38 to 4.13) · 2,875 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.153, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.565, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.644, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.143, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.287, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.8 (0.6 to 1) · 992 cases, Jan 2024 – Dec 2024
- USC Verdugo Hills HospitalGlendale, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of University of Southern California, which runs 4 hospitalsPatients rate it 3 of 5 · 65% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.19, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.5 to 1) · 396 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Glendale Adventist Medical Center
Behind the star rating — Deaths: 3 better, 5 the same, 0 worse of 8 measures. Safety: 3 better, 4 the same, 0 worse of 7 measures. Readmissions: 0 better, 6 the same, 3 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Pressure ulcer rateComplications and deaths | 0.08 (0 to 0.57) · 9,330 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.073 | Better | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.277 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.085 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.9 (0.01 to 1.79) · 1,817 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.75 (0.48 to 1.01) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 161.81 (119.07 to 204.55) · 188 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.1 · 70 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7 · 142 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11 · 312 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.7 · 787 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 11.9 · 1,340 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.3 · 352 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.3 · 3,776 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.31) · 11,108 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.18 (0 to 0.35) · 11,736 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3 (1.22 to 4.78) · 2,564 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.76 (0.19 to 3.33) · 882 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.38 (0.04 to 2.71) · 2,540 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.3 (2.34 to 14.26) · 947 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.26 (1.99 to 8.53) · 895 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.94 (0.47 to 3.41) · 431 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.7 · 112 cases | None | Apr 2023 – Mar 2025 |
| MRSA BacteremiaInfections | 0.686 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.978 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.234 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.7 · 368 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.2 · 930 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 30.6 · 370 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -4.5 · 1,036 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 30.9 · 1,549 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.9 · 1,397 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.3 (3.3 to 8.5) · 25 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.9 (7.5 to 15.5) · 25 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.9 · 105 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.4 · 68 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.9 · 171 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.2 (9.8 to 17.5) · 183 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.1 (0.8 to 1.4) · 416 cases | No different | Jan 2024 – Dec 2024 |
What patients said (759 patients answered, 15% of those asked)
| Cleanliness | 4 |
| Nurse communication | 2 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 3 |
| Room was "always" clean | 78% |
| Nurses "always" communicated well | 75% |
| Doctors "always" communicated well | 75% |
| Staff "always" explained | 59% |
| Yes, staff "did" give patients this information | 85% |
| Yes, staff "did" give patients information about help after discharge | 83% |
| Doctors "always" explained things so they could understand | 71% |
| Doctors "always" listened carefully | 72% |
| Doctors "always" treated them with courtesy and respect | 81% |
| Patients who gave a rating of "9" or "10" (high) | 66% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 71% |
| Nurses "always" listened carefully | 72% |
| Nurses "always" treated them with courtesy and respect | 82% |
| "Always" quiet at night | 51% |
| "YES", patients would definitely recommend the hospital | 69% |
| Staff "always" explained possible side effects | 47% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
See every measure and the patient survey for Keck Hospital of USC
Behind the star rating — Deaths: 0 better, 6 the same, 0 worse of 6 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 7 the same, 1 worse of 10 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.79 (0.6 to 0.97) | Better | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 5.33 (2.15 to 8.51) · 2,872 cases | Better | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 2.25 (0.38 to 4.13) · 2,875 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.153 | Better | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.565 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.644 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.143 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.287 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.8 (0.6 to 1) · 992 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.13 (0.47 to 1.79) · 3,513 cases | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 178.09 (145.37 to 210.81) · 267 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.9 · 63 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 7.7 · 134 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13.3 · 34 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.9 · 61 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3 · 2,086 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.21 (0.03 to 0.39) · 6,677 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.3 (0.12 to 0.48) · 7,784 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.38 (2.05 to 4.71) · 4,593 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2.02 (0.97 to 3.08) · 2,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.52 (0.5 to 2.55) · 3,742 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 2.61 (1.35 to 3.87) · 1,628 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.6 (0.17 to 1.02) · 5,896 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.9 · 128 cases | None | Apr 2023 – Mar 2025 |
| SSI - Abdominal HysterectomyInfections | 0.928 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.6 · 112 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.8 · 139 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 11.5 · 83 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 24.7 · 167 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -34.3 · 42 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.2 · 36 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 4.2 (2.8 to 6.3) · 103 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.7 (7.8 to 14.3) · 103 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 4.3 · 140 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 11.5 · 43 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 11.3 (8.9 to 14.5) · 1,774 cases | No different | Jan 2022 – Dec 2024 |
What patients said (744 patients answered, 28% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 72% |
| Nurses "always" communicated well | 80% |
| Doctors "always" communicated well | 83% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 77% |
| Doctors "always" listened carefully | 82% |
| Doctors "always" treated them with courtesy and respect | 89% |
| Patients who gave a rating of "9" or "10" (high) | 80% |
| Staff "always" explained new medications | 77% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 77% |
| Nurses "always" treated them with courtesy and respect | 87% |
| "Always" quiet at night | 58% |
| "YES", patients would definitely recommend the hospital | 82% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 89% |
See every measure and the patient survey for USC Verdugo Hills Hospital
Behind the star rating — Deaths: 2 better, 5 the same, 0 worse of 7 measures. Safety: 1 better, 6 the same, 0 worse of 7 measures. Readmissions: 1 better, 4 the same, 2 worse of 7 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.19 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.5 to 1) · 396 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.92 (0 to 1.94) · 627 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.9 (0.51 to 1.28) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 171.68 (110.02 to 233.35) · 27 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 8.4 · 73 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12 · 48 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 7.4 · 246 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 11.3 · 343 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.8 · 70 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.7 · 1,469 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.18 (0 to 0.4) · 3,522 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.24 (0.03 to 0.44) · 3,622 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.54 (1.21 to 5.88) · 541 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.45 (0 to 3.06) · 163 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.66 (1.03 to 4.29) · 511 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 11.7 (2.76 to 20.64) · 218 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.55 (0.5 to 8.6) · 189 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.69 (0.19 to 3.2) · 181 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.22 (0 to 1.01) · 2,841 cases | No different | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.263 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 1.733 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.2 · 48 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 21.6 · 273 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 2.6 · 298 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 28.2 · 377 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17 · 392 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.3 · 25 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.9 · 90 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 11.2 (8.5 to 14.8) · 881 cases | No different | Jan 2022 – Dec 2024 |
What patients said (413 patients answered, 23% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 2 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 3 |
| Quietness | 1 |
| Recommend hospital | 3 |
| Room was "always" clean | 77% |
| Nurses "always" communicated well | 76% |
| Doctors "always" communicated well | 75% |
| Staff "always" explained | 60% |
| Yes, staff "did" give patients this information | 84% |
| Yes, staff "did" give patients information about help after discharge | 82% |
| Doctors "always" explained things so they could understand | 73% |
| Doctors "always" listened carefully | 74% |
| Doctors "always" treated them with courtesy and respect | 80% |
| Patients who gave a rating of "9" or "10" (high) | 64% |
| Staff "always" explained new medications | 71% |
| Nurses "always" explained things so they could understand | 72% |
| Nurses "always" listened carefully | 74% |
| Nurses "always" treated them with courtesy and respect | 82% |
| "Always" quiet at night | 36% |
| "YES", patients would definitely recommend the hospital | 65% |
| Staff "always" explained possible side effects | 49% |
| Yes, staff "did" give patients information about possible symptoms | 85% |
Original Medicare doctor bills
$7,782,866
Medicare paid this office $7,782,866 for 1,041 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg | 78 | $1,007,125 | None |
| Injection, pembrolizumab, 1 mg | 15 | $1,001,572 | None |
| Injection, bevacizumab-adcd (vegzelma), biosimilar, 10 mg | 14 | $377,583 | $50 |
| Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg | 53 | $311,672 | None |
| Injection, denosumab, 1 mg | 65 | $300,790 | None |
See all 45 services
| Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg | 78 | $1,007,125 | None |
| Injection, pembrolizumab, 1 mg | 15 | $1,001,572 | None |
| Injection, bevacizumab-adcd (vegzelma), biosimilar, 10 mg | 14 | $377,583 | $50 |
| Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg | 53 | $311,672 | None |
| Injection, denosumab, 1 mg | 65 | $300,790 | None |
| Return visit (30+ min) | 648 | $291,218 | $105 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 247 | $179,877 | $97 |
| Administration of chemotherapy into vein, 1 hour or less | 85 | $87,604 | $115 |
| Short return visit (20+ min) | 494 | $74,796 | $72 |
| Injection, rituximab-arrx, biosimilar, (riabni), 10 mg | 14 | $63,504 | $32 |
| Injection, ferric derisomaltose, 10 mg | 27 | $48,415 | None |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 140 | $38,406 | $54 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 159 | $28,397 | $24 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 180 | $27,670 | $142 |
| New patient visit (60+ min) | 142 | $24,996 | $176 |
| Insertion of needle into vein for collection of blood sample | 655 | $18,853 | $9 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 626 | $18,614 | $8 |
| Injection of drug or substance under skin or into muscle | 202 | $14,488 | $12 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 100 | $14,064 | $17 |
| Long return visit (40+ min) | 62 | $10,954 | $152 |
| Administration of additional new drug or substance into vein, 1 hour or less | 34 | $10,769 | $56 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 41 | $10,238 | $30 |
| Blood test, comprehensive group of blood chemicals | 259 | $9,915 | $10 |
| Administration of chemotherapy into vein, each additional hour | 46 | $5,719 | $24 |
| Assessment of emotional or behavioral problems | 737 | $5,516 | $4 |
| Infusion into a vein for hydration, 31-60 minutes | 47 | $4,101 | $28 |
| Injection, fulvestrant, 25 mg | 17 | $2,170 | None |
| Administration of additional new drug or substance into vein using push technique | 11 | $1,830 | $40 |
| Injection, dexamethasone sodium phosphate, 1 mg | 158 | $1,699 | None |
| Infusion into a vein for hydration, each additional hour | 50 | $1,692 | $11 |
| Injection, epoetin alfa, (for non-esrd use), 1000 units | 33 | $1,295 | None |
| Injection, pegfilgrastim, excludes biosimilar, 0.5 mg | 22 | $1,033 | None |
| Leuprolide acetate (for depot suspension), 7.5 mg | 22 | $948 | None |
| Aspiration of bone marrow sample for diagnosis | 11 | $912 | $83 |
| Injection of additional new drug or substance into vein | 19 | $838 | $14 |
| Injection, palonosetron hcl, 25 mcg | 23 | $773 | None |
| Injection, zoledronic acid, 1 mg | 14 | $703 | None |
| Injection, carboplatin, 50 mg | 15 | $685 | None |
| Injection of drug or substance into vein | 13 | $631 | $33 |
| Injection, diphenhydramine hcl, up to 50 mg | 155 | $621 | None |
| Injection, paclitaxel, 1 mg | 11 | $481 | None |
| Injection, filgrastim-sndz, biosimilar, (zarxio), 1 microgram | 28 | $275 | $0 |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 42 | $220 | None |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 49 | $152 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 24 | $135 | None |
Procedures year by year
| Procedure | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Aspiration of bone marrow sample for diagnosis | 20 | 24 | 39 | 16 | 19 | 11 |
| Biopsy of bone marrow | 20 | 24 | 39 | 17 | 19 | – |
Times billed to Original Medicare each year. A blank year means fewer than 11 people had it, or none: Medicare does not publish smaller counts. Medicare Advantage patients are not included.
Who their Medicare patients are
1,041 Original Medicare patients in 2024. Average age 75 · Under 65 6% · 85 and older 17% · Women 63% · Also on Medicaid 79% · Health risk score 2.41. Above the middle of the specialty; the typical hematology-oncology clinician is at 2.04.
Conditions among them: High blood pressure 75% · Coronary heart disease 58% · Diabetes 56% · Cancer 48% · Depression 43% · Chronic kidney disease 42% · Heart failure 39% · COPD 27% · Atrial fibrillation 24% · Dementia 23% · Stroke 15%.
The office billed $28,406,756, Medicare allowed $9,787,655 and paid $7,782,866; for 285,154 services of 122 kinds; $6,887,431 of it was for drugs given in the office and $895,435 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 1,041 | 285,154 | 75 | 2.41 | $28,406,756 | $7,782,866 |
| 2023 | 1,124 | 161,870 | 75 | 2.24 | $10,648,695 | $2,779,291 |
| 2022 | 1,048 | 124,277 | 75 | 2.17 | $6,198,337 | $1,991,968 |
| 2021 | 961 | 214,083 | 75 | 2.32 | $6,913,793 | $2,809,190 |
| 2020 | 952 | 470,160 | 75 | 2.36 | $11,137,460 | $4,312,121 |
| 2019 | 1,045 | 513,432 | 75 | 2.57 | $8,817,299 | $3,516,293 |
| 2018 | 1,050 | 541,079 | 74 | 2.42 | $8,389,326 | $3,547,217 |
| 2017 | 888 | 436,042 | 75 | 2.45 | $6,682,488 | $2,693,791 |
| 2016 | 821 | 503,996 | 75 | 2.58 | $5,619,837 | $2,218,547 |
| 2015 | 697 | 198,872 | 76 | 2.44 | $4,912,277 | $1,903,812 |
| 2014 | 618 | 173,027 | 75 | 2.43 | $4,517,320 | $1,775,996 |
| 2013 | 727 | 136,155 | 76 | 2.50 | $4,557,451 | $1,753,775 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 51 services
| Injection, pembrolizumab, 1 mg | 16 | $357,307 | None |
| Return visit (30+ min) | 721 | $319,547 | $104 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 288 | $193,657 | $99 |
| Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg | 72 | $178,321 | None |
| Administration of chemotherapy into vein, 1 hour or less | 103 | $88,082 | $119 |
| Injection, denosumab, 1 mg | 54 | $72,373 | None |
| Short return visit (20+ min) | 431 | $57,249 | $75 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 140 | $36,772 | $56 |
| Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg | 11 | $34,918 | None |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 209 | $30,937 | $143 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 162 | $30,661 | $26 |
| New patient visit (60+ min) | 176 | $30,160 | $171 |
| Injection, ferric derisomaltose, 10 mg | 14 | $26,022 | None |
| Administration of additional new drug or substance into vein, 1 hour or less | 55 | $21,158 | $59 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 708 | $20,672 | $8 |
| Injection, fulvestrant (fresenius kabi) not therapeutically equivalent to j9395, 25 mg | 12 | $16,621 | None |
| Injection of drug or substance under skin or into muscle | 157 | $13,644 | $12 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 92 | $12,770 | $18 |
| Insertion of needle into vein for collection of blood sample | 662 | $12,273 | $8 |
| Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg | 15 | $12,254 | $21 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 11 | $10,606 | $66 |
| Administration of chemotherapy into vein, each additional hour | 63 | $9,820 | $25 |
| Injection, pegfilgrastim, excludes biosimilar, 0.5 mg | 25 | $9,723 | None |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 29 | $7,427 | $29 |
| Blood test, comprehensive group of blood chemicals | 215 | $7,142 | $10 |
| Infusion into a vein for hydration, 31-60 minutes | 63 | $6,164 | $29 |
| Long return visit (40+ min) | 37 | $5,636 | $141 |
| Injection, filgrastim-sndz, biosimilar, (zarxio), 1 microgram | 46 | $5,291 | $0 |
| Assessment of emotional or behavioral problems | 606 | $4,637 | $4 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 16 | $3,071 | None |
| Administration of additional new drug or substance into vein using push technique | 18 | $2,890 | $50 |
| Biopsy of bone marrow | 17 | $2,770 | $146 |
| Infusion into a vein for hydration, each additional hour | 62 | $2,244 | $11 |
| Aspiration of bone marrow sample for diagnosis | 17 | $1,297 | $68 |
| Injection, fulvestrant (teva) not therapeutically equivalent to j9395, 25 mg | 13 | $998 | None |
| Injection, palonosetron hcl, 25 mcg | 58 | $894 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 160 | $780 | None |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 12 | $588 | $17 |
| Injection of additional new drug or substance into vein | 18 | $503 | $14 |
| Injection, carboplatin, 50 mg | 20 | $500 | None |
| Injection, oxaliplatin, 0.5 mg | 14 | $420 | None |
| Injection, irinotecan, 20 mg | 14 | $419 | None |
| Injection, paclitaxel, 1 mg | 14 | $346 | None |
| Injection, fulvestrant, 25 mg | 11 | $329 | None |
| Injection, fosaprepitant, 1 mg | 17 | $310 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 156 | $306 | None |
| Injection, zoledronic acid, 1 mg | 32 | $239 | None |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 27 | $123 | None |
| Injection, atropine sulfate, 0.01 mg | 14 | $114 | None |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 21 | $87 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 33 | $62 | None |
2022: 47 services
| Return visit (30+ min) | 708 | $306,183 | $107 |
| Injection, atezolizumab, 10 mg | 14 | $274,885 | None |
| Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg | 47 | $207,765 | None |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 258 | $147,144 | $86 |
| Injection, pembrolizumab, 1 mg | 15 | $143,974 | None |
| Administration of chemotherapy into vein, 1 hour or less | 89 | $78,495 | $125 |
| Short return visit (20+ min) | 404 | $50,032 | $74 |
| Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a | 138 | $38,109 | $159 |
| Injection, denosumab, 1 mg | 38 | $36,563 | None |
| New patient visit (60+ min) | 187 | $33,342 | $178 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 108 | $29,732 | $60 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 163 | $27,204 | $164 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 147 | $26,758 | $27 |
| Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg | 15 | $20,804 | $23 |
| Administration of additional new drug or substance into vein, 1 hour or less | 51 | $19,413 | $62 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 653 | $18,267 | $8 |
| Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | 20 | $12,226 | $1 |
| Injection of drug or substance under skin or into muscle | 149 | $11,887 | $12 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 73 | $11,306 | $19 |
| Administration of chemotherapy into vein, each additional hour | 55 | $8,828 | $27 |
| Insertion of needle into vein for collection of blood sample | 766 | $8,420 | $3 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 30 | $6,625 | $29 |
| Long return visit (40+ min) | 37 | $6,464 | $158 |
| Injection, pegfilgrastim, excludes biosimilar, 0.5 mg | 36 | $6,413 | None |
| Infusion into a vein for hydration, 31-60 minutes | 50 | $6,160 | $31 |
| Blood test, comprehensive group of blood chemicals | 153 | $3,963 | $10 |
| Injection, filgrastim-sndz, biosimilar, (zarxio), 1 microgram | 27 | $2,653 | $0 |
| Biopsy of bone marrow | 15 | $2,553 | $150 |
| Infusion into a vein for hydration, each additional hour | 46 | $2,321 | $12 |
| Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a | 13 | $2,069 | $159 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 17 | $1,910 | None |
| Aspiration of bone marrow sample for diagnosis | 14 | $1,154 | $72 |
| Injection, fulvestrant, 25 mg | 13 | $1,022 | None |
| Injection, palonosetron hcl, 25 mcg | 54 | $515 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 143 | $493 | None |
| Injection, zoledronic acid, 1 mg | 26 | $471 | None |
| Injection, paclitaxel, 1 mg | 12 | $317 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 139 | $286 | None |
| Injection of additional new drug or substance into vein | 13 | $219 | $15 |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 33 | $184 | None |
| Injection, atropine sulfate, 0.01 mg | 11 | $123 | None |
| Assessment of emotional or behavioral problems | 15 | $71 | $4 |
| Injection, fosaprepitant, 1 mg | 16 | $68 | None |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 15 | $63 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 20 | $49 | None |
| Injection, carboplatin, 50 mg | 14 | $0 | None |
| Injection, rituximab-abbs, biosimilar, (truxima), 10 mg | 12 | $0 | $0 |
2021: 52 services
| Injection, atezolizumab, 10 mg | 14 | $410,040 | None |
| Return visit (30+ min) | 701 | $385,456 | $109 |
| Injection, pembrolizumab, 1 mg | 12 | $349,659 | None |
| Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg | 40 | $226,693 | None |
| Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a | 202 | $175,384 | $160 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 236 | $113,109 | $88 |
| Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg | 11 | $100,127 | $47 |
| Administration of chemotherapy into vein, 1 hour or less | 89 | $85,455 | $134 |
| Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg | 13 | $66,212 | $36 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 163 | $57,151 | $66 |
| Injection, denosumab, 1 mg | 36 | $45,087 | None |
| Injection, ferric carboxymaltose, 1 mg | 31 | $35,101 | None |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 140 | $29,396 | $29 |
| New patient visit (60+ min) | 164 | $28,765 | $175 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 160 | $28,465 | $171 |
| Injection, fulvestrant, 25 mg | 16 | $27,824 | None |
| Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | 39 | $27,812 | $1 |
| Short return visit (20+ min) | 269 | $27,312 | $69 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 623 | $21,395 | $8 |
| Administration of additional new drug or substance into vein, 1 hour or less | 39 | $14,985 | $67 |
| Injection of drug or substance under skin or into muscle | 143 | $12,441 | $12 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 84 | $11,866 | $20 |
| Injection, filgrastim-sndz, biosimilar, (zarxio), 1 microgram | 36 | $9,998 | $0 |
| Injection, epoetin alfa, (for non-esrd use), 1000 units | 16 | $9,312 | None |
| Insertion of needle into vein for collection of blood sample | 683 | $9,225 | $3 |
| Administration of chemotherapy into vein, each additional hour | 44 | $8,963 | $29 |
| Long return visit (40+ min) | 46 | $8,399 | $156 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 28 | $5,133 | $30 |
| Blood test, comprehensive group of blood chemicals | 110 | $2,957 | $11 |
| Biopsy of bone marrow | 33 | $2,773 | $71 |
| Injection, palonosetron hcl, 25 mcg | 44 | $2,509 | None |
| Administration of additional new drug or substance into vein using push technique | 11 | $2,469 | $57 |
| Injection, zoledronic acid, 1 mg | 31 | $2,468 | None |
| Injection, fosaprepitant, 1 mg | 13 | $2,058 | None |
| Infusion into a vein for hydration, 31-60 minutes | 27 | $1,837 | $33 |
| Injection of drug or substance into vein | 29 | $1,352 | $39 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 16 | $1,219 | None |
| Aspiration of bone marrow sample for diagnosis | 33 | $1,074 | $28 |
| Injection, dexamethasone sodium phosphate, 1 mg | 137 | $1,047 | None |
| Injection, oxaliplatin, 0.5 mg | 11 | $749 | None |
| Injection of additional new drug or substance into vein | 19 | $642 | $15 |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 14 | $639 | $19 |
| Infusion into a vein for hydration, each additional hour | 20 | $586 | $13 |
| Injection, irinotecan, 20 mg | 11 | $419 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 128 | $335 | None |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 39 | $282 | None |
| Injection, magnesium sulfate, per 500 mg | 41 | $228 | None |
| Injection, atropine sulfate, 0.01 mg | 11 | $150 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 22 | $66 | None |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 11 | $35 | None |
| Injection, lorazepam, 2 mg | 22 | $18 | None |
| Injection, heparin sodium, (heparin lock flush), per 10 units | 13 | $8 | None |
2020: 50 services
| Injection, pembrolizumab, 1 mg | 12 | $623,473 | None |
| Return visit (30+ min) | 698 | $357,574 | $91 |
| Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg | 12 | $292,155 | $50 |
| Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a | 200 | $178,161 | $159 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 284 | $147,618 | $91 |
| Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg | 11 | $130,883 | $52 |
| Injection, immune globulin (privigen), intravenous, non-lyophilized (e.g., liquid), 500 mg | 29 | $129,083 | None |
| Administration of chemotherapy into vein, 1 hour or less | 88 | $116,002 | $132 |
| Injection, filgrastim-sndz, biosimilar, (zarxio), 1 microgram | 25 | $85,276 | $0 |
| Injection, denosumab, 1 mg | 29 | $67,869 | None |
| Injection, fulvestrant, 25 mg | 13 | $65,013 | None |
| Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | 62 | $57,875 | $1 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 157 | $54,585 | $66 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 145 | $33,405 | $29 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 173 | $31,081 | $172 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 591 | $21,146 | $8 |
| Administration of additional new drug or substance into vein, 1 hour or less | 42 | $20,254 | $64 |
| New patient visit (60+ min) | 117 | $19,786 | $169 |
| Short return visit (20+ min) | 187 | $18,672 | $61 |
| Injection, epoetin alfa, (for non-esrd use), 1000 units | 16 | $17,759 | None |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 86 | $14,440 | $20 |
| Administration of chemotherapy into vein, each additional hour | 48 | $13,940 | $28 |
| Injection of drug or substance under skin or into muscle | 118 | $10,657 | $12 |
| Cyclophosphamide, 100 mg | 11 | $10,632 | None |
| Injection, palonosetron hcl, 25 mcg | 50 | $9,831 | None |
| Insertion of needle into vein for collection of blood sample | 618 | $8,686 | $3 |
| Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a | 13 | $7,469 | $159 |
| Injection, fosaprepitant, 1 mg | 14 | $7,033 | None |
| Administration of additional new drug or substance into vein using push technique | 17 | $5,496 | $56 |
| Long return visit (40+ min) | 30 | $5,322 | $124 |
| Blood test, comprehensive group of blood chemicals | 102 | $3,150 | $10 |
| Injection of additional new drug or substance into vein | 43 | $3,127 | $15 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 21 | $2,828 | $29 |
| Injection, zoledronic acid, 1 mg | 21 | $2,302 | None |
| Injection, oxaliplatin, 0.5 mg | 11 | $1,826 | None |
| Biopsy of bone marrow | 15 | $1,665 | $69 |
| Injection, dexamethasone sodium phosphate, 1 mg | 139 | $1,354 | None |
| Injection, paclitaxel, 1 mg | 14 | $919 | None |
| Injection, fluorouracil, 500 mg | 12 | $834 | None |
| Injection of drug or substance into vein | 15 | $741 | $37 |
| Injection, carboplatin, 50 mg | 16 | $731 | None |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 66 | $527 | None |
| Infusion into a vein for hydration, each additional hour | 16 | $515 | $11 |
| Injection, diphenhydramine hcl, up to 50 mg | 137 | $473 | None |
| Injection, magnesium sulfate, per 500 mg | 58 | $445 | None |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 31 | $181 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 19 | $117 | None |
| Aspiration of bone marrow sample for diagnosis | 15 | $106 | $4 |
| Injection, heparin sodium, (heparin lock flush), per 10 units | 22 | $84 | None |
| Injection, lorazepam, 2 mg | 13 | $9 | None |
2019: 60 services
| Return visit (30+ min) | 722 | $391,743 | $90 |
| Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a | 209 | $195,059 | $157 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 370 | $165,567 | $87 |
| Injection, rituximab, 10 mg | 12 | $149,643 | None |
| Injection, pembrolizumab, 1 mg | 12 | $146,888 | None |
| Injection, denosumab, 1 mg | 32 | $143,797 | None |
| Injection, bevacizumab, 10 mg | 13 | $139,301 | None |
| Administration of chemotherapy into vein, 1 hour or less | 106 | $138,379 | $128 |
| Injection, pegfilgrastim-jmdb (fulphila), biosimilar, 0.5 mg | 13 | $114,612 | $273 |
| Injection, filgrastim-sndz, biosimilar, (zarxio), 1 microgram | 39 | $104,020 | $0 |
| Injection, trastuzumab, excludes biosimilar, 10 mg | 12 | $100,628 | None |
| Injection, immune globulin (privigen), intravenous, non-lyophilized (e.g., liquid), 500 mg | 27 | $67,064 | None |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 180 | $66,748 | $65 |
| Injection, epoetin alfa, (for non-esrd use), 1000 units | 26 | $45,198 | None |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 163 | $43,793 | $28 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 262 | $43,480 | $162 |
| Injection, palonosetron hcl, 25 mcg | 67 | $40,811 | None |
| Injection, ferric carboxymaltose, 1 mg | 30 | $36,721 | None |
| Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | 44 | $34,890 | $1 |
| Administration of additional new drug or substance into vein, 1 hour or less | 59 | $32,406 | $62 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 600 | $25,287 | $8 |
| New patient visit (60+ min) | 126 | $20,325 | $161 |
| Injection, fosaprepitant, 1 mg | 16 | $17,457 | None |
| Administration of chemotherapy into vein, each additional hour | 73 | $17,345 | $28 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 103 | $15,415 | $19 |
| Injection of drug or substance under skin or into muscle | 137 | $15,256 | $15 |
| Short return visit (20+ min) | 147 | $14,928 | $63 |
| Administration of chemotherapy into vein using push technique | 14 | $11,112 | $97 |
| Insertion of needle into vein for collection of blood sample | 601 | $9,032 | $3 |
| Administration of prolonged chemotherapy into vein | 11 | $8,794 | $126 |
| Administration of additional new drug or substance into vein using push technique | 21 | $6,991 | $53 |
| Injection of additional new drug or substance into vein | 79 | $6,970 | $15 |
| Long return visit (40+ min) | 38 | $5,515 | $120 |
| Blood test, comprehensive group of blood chemicals | 142 | $5,341 | $12 |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 17 | $4,068 | None |
| Injection, oxaliplatin, 0.5 mg | 12 | $3,816 | None |
| Injection, irinotecan, 20 mg | 12 | $3,715 | None |
| Injection, paclitaxel, 1 mg | 22 | $2,295 | None |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 15 | $2,135 | $26 |
| Injection, dexamethasone sodium phosphate, 1 mg | 160 | $1,861 | None |
| Injection, carboplatin, 50 mg | 26 | $1,688 | None |
| Infusion into a vein for hydration, each additional hour | 20 | $1,521 | $12 |
| Injection, calcium gluconate (fresenius kabi), per 10 ml | 12 | $1,515 | None |
| Injection, magnesium sulfate, per 500 mg | 75 | $1,472 | None |
| Biopsy of bone marrow | 14 | $1,400 | $70 |
| Injection, zoledronic acid, 1 mg | 13 | $1,218 | None |
| Injection, fluorouracil, 500 mg | 14 | $1,192 | None |
| Injection, leucovorin calcium, per 50 mg | 11 | $1,158 | None |
| Aspiration of bone marrow sample for diagnosis | 14 | $1,093 | $55 |
| Injection of drug or substance into vein | 18 | $820 | $36 |
| Injection, cisplatin, powder or solution, 10 mg | 11 | $792 | None |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 93 | $657 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 154 | $618 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 36 | $395 | None |
| Injection, heparin sodium, (heparin lock flush), per 10 units | 23 | $284 | None |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 34 | $243 | None |
| Injection, atropine sulfate, 0.01 mg | 12 | $175 | None |
| Injection, mannitol, 25% in 50 ml | 11 | $156 | None |
| Injection, potassium chloride, per 2 meq | 19 | $92 | None |
| Injection, lorazepam, 2 mg | 17 | $15 | None |
2018: 57 services
| Return visit (30+ min) | 730 | $373,647 | $89 |
| Injection, immune globulin, intravenous, lyophilized (e.g., powder), not otherwise specified, 500 mg | 33 | $291,999 | None |
| Injection, denosumab, 1 mg | 43 | $182,836 | None |
| Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a | 190 | $172,010 | $157 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 336 | $162,038 | $88 |
| Injection, filgrastim-sndz, biosimilar, (zarxio), 1 microgram | 54 | $123,247 | $1 |
| Injection, ferric carboxymaltose, 1 mg | 79 | $102,081 | None |
| Administration of chemotherapy into vein, 1 hour or less | 89 | $95,637 | $129 |
| Injection, immune globulin (privigen), intravenous, non-lyophilized (e.g., liquid), 500 mg | 25 | $94,517 | None |
| Injection, bevacizumab, 10 mg | 13 | $77,268 | None |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 176 | $69,394 | $66 |
| Injection, trastuzumab, excludes biosimilar, 10 mg | 13 | $66,686 | None |
| Injection, palonosetron hcl, 25 mcg | 59 | $55,184 | None |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 229 | $39,638 | $166 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 111 | $30,635 | $28 |
| Administration of additional new drug or substance into vein, 1 hour or less | 51 | $28,426 | $62 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 607 | $27,866 | $9 |
| New patient visit (60+ min) | 168 | $27,213 | $162 |
| Injection, epoetin alfa, (for non-esrd use), 1000 units | 23 | $25,526 | None |
| Injection of drug or substance under skin or into muscle | 155 | $18,133 | $18 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 13 | $17,014 | $73 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 92 | $14,373 | $20 |
| Injection, fosaprepitant, 1 mg | 18 | $13,892 | None |
| Administration of prolonged chemotherapy into vein | 15 | $10,708 | $127 |
| Short return visit (20+ min) | 106 | $10,196 | $62 |
| Administration of chemotherapy into vein, each additional hour | 41 | $9,804 | $28 |
| Insertion of needle into vein for collection of blood sample | 611 | $8,945 | $3 |
| Administration of additional new drug or substance into vein using push technique | 24 | $6,353 | $52 |
| Injection of additional new drug or substance into vein | 73 | $6,161 | $16 |
| Blood test, comprehensive group of blood chemicals | 141 | $6,045 | $13 |
| Aspiration of bone marrow sample for diagnosis | 25 | $4,581 | $153 |
| Injection, oxaliplatin, 0.5 mg | 13 | $4,482 | None |
| Long return visit (40+ min) | 31 | $4,269 | $126 |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 13 | $3,406 | None |
| Injection, calcium gluconate (fresenius kabi), per 10 ml | 13 | $2,861 | None |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 16 | $2,700 | $27 |
| Injection, zoledronic acid, 1 mg | 18 | $2,452 | None |
| Biopsy of bone marrow | 25 | $2,083 | $69 |
| Injection, carboplatin, 50 mg | 23 | $1,858 | None |
| Infusion into a vein for hydration, 31-60 minutes | 22 | $1,546 | $43 |
| Injection, leucovorin calcium, per 50 mg | 13 | $1,515 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 107 | $1,305 | None |
| Infusion into a vein for hydration, each additional hour | 21 | $1,274 | $12 |
| Injection, fluorouracil, 500 mg | 16 | $1,127 | None |
| Injection, paclitaxel, 1 mg | 13 | $1,117 | None |
| Injection, magnesium sulfate, per 500 mg | 76 | $816 | None |
| Injection of drug or substance into vein | 13 | $766 | $43 |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 87 | $613 | None |
| Injection, cisplatin, powder or solution, 10 mg | 11 | $466 | None |
| Injection, heparin sodium, (heparin lock flush), per 10 units | 30 | $370 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 108 | $335 | None |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 45 | $309 | None |
| Influenza vaccine, trivalent, split virus, preservative-free, 0.5 ml dosage | 13 | $252 | $19 |
| Injection, ondansetron hydrochloride, per 1 mg | 37 | $193 | None |
| Injection, mannitol, 25% in 50 ml | 11 | $93 | None |
| Injection, potassium chloride, per 2 meq | 17 | $62 | None |
| Injection, lorazepam, 2 mg | 18 | $20 | None |
2017: 43 services
| Injection, immune globulin, intravenous, lyophilized (e.g., powder), not otherwise specified, 500 mg | 33 | $342,101 | None |
| Return visit (30+ min) | 636 | $282,704 | $89 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 276 | $147,930 | $89 |
| Injection, filgrastim-sndz, biosimilar, (zarxio), 1 microgram | 38 | $132,968 | $1 |
| Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a | 145 | $132,026 | $157 |
| Injection, ferric carboxymaltose, 1 mg | 51 | $70,991 | None |
| Administration of chemotherapy into vein, 1 hour or less | 57 | $55,497 | $124 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 143 | $45,940 | $61 |
| Injection, denosumab, 1 mg | 26 | $44,134 | None |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 181 | $32,152 | $167 |
| Injection, palonosetron hcl, 25 mcg | 28 | $24,846 | None |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 501 | $23,339 | $10 |
| Injection of drug or substance under skin or into muscle | 113 | $20,377 | $22 |
| New patient visit (60+ min) | 115 | $19,018 | $164 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 82 | $18,672 | $27 |
| Injection, epoetin alfa, (for non-esrd use), 1000 units | 19 | $12,710 | None |
| Administration of additional new drug or substance into vein, 1 hour or less | 32 | $11,863 | $59 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 14 | $8,412 | $67 |
| Insertion of needle into vein for collection of blood sample | 515 | $6,913 | $3 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 72 | $6,186 | $16 |
| Carcinoembryonic antigen (cea) protein level | 116 | $5,888 | $25 |
| Injection, zoledronic acid, 1 mg | 28 | $5,142 | None |
| Blood test, comprehensive group of blood chemicals | 86 | $5,098 | $14 |
| Short return visit (20+ min) | 50 | $3,504 | $60 |
| Administration of chemotherapy into vein, each additional hour | 21 | $3,411 | $25 |
| Administration of additional new drug or substance into vein using push technique | 13 | $3,350 | $57 |
| Injection of additional new drug or substance into vein | 40 | $3,326 | $20 |
| Long return visit (40+ min) | 23 | $2,871 | $120 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 17 | $2,499 | $26 |
| Aspiration of bone marrow sample for diagnosis | 12 | $1,971 | $152 |
| Biopsy of bone marrow | 13 | $1,286 | $86 |
| Injection, carboplatin, 50 mg | 12 | $1,155 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 72 | $704 | None |
| Immunologic analysis for detection of tumor antigen, quantitative; ca 19-9 | 14 | $504 | $28 |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 38 | $346 | None |
| Psa (prostate specific antigen) measurement, total | 11 | $346 | $25 |
| Injection, magnesium sulfate, per 500 mg | 45 | $335 | None |
| Injection, heparin sodium, (heparin lock flush), per 10 units | 29 | $316 | None |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 57 | $298 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 70 | $224 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 27 | $156 | None |
| Injection, potassium chloride, per 2 meq | 12 | $36 | None |
| Injection, lorazepam, 2 mg | 11 | $11 | None |
2016: 45 services
| Return visit (30+ min) | 556 | $272,389 | $88 |
| Injection, filgrastim-sndz, biosimilar, (zarxio), 1 microgram | 43 | $217,803 | $1 |
| Injection, immune globulin, intravenous, lyophilized (e.g., powder), not otherwise specified, 500 mg | 23 | $216,894 | None |
| Injection, rituximab, 100 mg | 11 | $132,396 | None |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 272 | $122,799 | $88 |
| Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a | 92 | $69,306 | $157 |
| Administration of chemotherapy into vein, 1 hour or less | 60 | $67,600 | $121 |
| Injection, ferric carboxymaltose, 1 mg | 44 | $55,668 | None |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 126 | $40,642 | $60 |
| Injection, palonosetron hcl, 25 mcg | 39 | $39,307 | None |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 177 | $31,650 | $171 |
| Injection, denosumab, 1 mg | 18 | $29,263 | None |
| Injection of drug or substance under skin or into muscle | 110 | $28,338 | $22 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 448 | $22,722 | $10 |
| New patient visit (60+ min) | 132 | $22,344 | $169 |
| Injection, sargramostim (gm-csf), 50 mcg | 15 | $19,529 | None |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 82 | $17,027 | $26 |
| Injection, epoetin alfa, (for non-esrd use), 1000 units | 14 | $13,682 | None |
| Administration of additional new drug or substance into vein, 1 hour or less | 32 | $11,325 | $56 |
| Injection, zoledronic acid, 1 mg | 30 | $10,263 | None |
| Insertion of needle into vein for collection of blood sample | 468 | $6,670 | $3 |
| Administration of chemotherapy into vein, each additional hour | 40 | $6,255 | $25 |
| Administration of additional new drug or substance into vein using push technique | 14 | $4,601 | $56 |
| Long return visit (40+ min) | 31 | $4,572 | $120 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 66 | $4,302 | $16 |
| Blood test, comprehensive group of blood chemicals | 93 | $4,301 | $14 |
| Injection of additional new drug or substance into vein | 45 | $4,068 | $20 |
| Short return visit (20+ min) | 44 | $3,666 | $62 |
| Injection, heparin sodium, (heparin lock flush), per 10 units | 60 | $3,594 | None |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 15 | $2,734 | $27 |
| Biopsy of bone marrow | 14 | $2,246 | $150 |
| Return visit (30+ min) | 27 | $2,125 | $52 |
| Injection, paclitaxel, 1 mg | 13 | $1,309 | None |
| Aspiration of bone marrow sample for diagnosis | 12 | $963 | $74 |
| Injection, carboplatin, 50 mg | 12 | $948 | None |
| Injection of drug or substance into vein | 17 | $944 | $50 |
| Injection, dexamethasone sodium phosphate, 1 mg | 56 | $569 | None |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 32 | $553 | None |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 11 | $384 | $17 |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 66 | $316 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 70 | $195 | None |
| Injection, magnesium sulfate, per 500 mg | 55 | $169 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 15 | $120 | None |
| Injection, potassium chloride, per 2 meq | 11 | $21 | None |
| Injection, lorazepam, 2 mg | 16 | $13 | None |
2015: 39 services
| Injection, immune globulin, intravenous, lyophilized (e.g., powder), not otherwise specified, 500 mg | 34 | $260,074 | None |
| Return visit (30+ min) | 465 | $251,262 | $90 |
| Injection, sargramostim (gm-csf), 50 mcg | 45 | $168,897 | None |
| Injection, rituximab, 100 mg | 18 | $155,791 | None |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 221 | $108,801 | $88 |
| Injection, epoetin alfa, (for non-esrd use), 1000 units | 37 | $63,726 | None |
| Administration of chemotherapy into vein, 1 hour or less | 65 | $53,251 | $119 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 130 | $51,714 | $61 |
| Injection, ferric carboxymaltose, 1 mg | 35 | $46,996 | None |
| Injection, palonosetron hcl, 25 mcg | 38 | $39,438 | None |
| Injection of drug or substance under skin or into muscle | 119 | $29,370 | $22 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 426 | $22,771 | $10 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 129 | $22,525 | $168 |
| Injection, zoledronic acid, 1 mg | 29 | $19,783 | None |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 92 | $19,145 | $26 |
| New patient visit (60+ min) | 108 | $18,124 | $168 |
| Administration of additional new drug or substance into vein, 1 hour or less | 33 | $11,369 | $55 |
| Short return visit (20+ min) | 101 | $10,949 | $56 |
| Injection, denosumab, 1 mg | 11 | $9,103 | None |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 80 | $7,606 | $16 |
| Administration of chemotherapy into vein, each additional hour | 41 | $7,483 | $25 |
| Insertion of needle into vein for collection of blood sample | 433 | $6,509 | $3 |
| Injection, heparin sodium, (heparin lock flush), per 10 units | 66 | $5,853 | None |
| Injection of additional new drug or substance into vein | 41 | $4,375 | $19 |
| Return visit (30+ min) | 29 | $4,072 | $67 |
| Long return visit (40+ min) | 21 | $3,138 | $126 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 12 | $3,018 | $29 |
| Blood test, comprehensive group of blood chemicals | 58 | $2,900 | $14 |
| Biopsy of bone marrow | 14 | $2,402 | $150 |
| Injection of drug or substance into vein | 15 | $1,283 | $51 |
| Injection, dexamethasone sodium phosphate, 1 mg | 85 | $1,192 | None |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 17 | $1,044 | $18 |
| Injection, carboplatin, 50 mg | 15 | $741 | None |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 30 | $336 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 83 | $244 | None |
| Injection, magnesium sulfate, per 500 mg | 52 | $148 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 23 | $79 | None |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 29 | $37 | None |
| Injection, potassium chloride, per 2 meq | 12 | $21 | None |
2014: 41 services
| Return visit (30+ min) | 412 | $227,088 | $88 |
| Injection, sargramostim (gm-csf), 50 mcg | 41 | $171,666 | None |
| Injection, rituximab, 100 mg | 23 | $162,248 | None |
| Injection, immune globulin, intravenous, lyophilized (e.g., powder), not otherwise specified, 500 mg | 21 | $124,305 | None |
| Injection, epoetin alfa, (for non-esrd use), 1000 units | 60 | $98,334 | None |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 217 | $98,193 | $86 |
| Administration of chemotherapy into vein, 1 hour or less | 65 | $59,619 | $118 |
| Injection, tbo-filgrastim, 5 micrograms | 13 | $58,163 | None |
| Injection, palonosetron hcl, 25 mcg | 43 | $40,416 | None |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 99 | $37,333 | $61 |
| Injection of drug or substance under skin or into muscle | 116 | $32,385 | $22 |
| Injection, zoledronic acid, 1 mg | 24 | $28,416 | None |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 147 | $26,265 | $167 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 361 | $20,836 | $10 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 81 | $19,061 | $26 |
| New patient visit (60+ min) | 98 | $15,920 | $162 |
| Injection, docetaxel, 1 mg | 13 | $14,222 | None |
| Injection, denosumab, 1 mg | 12 | $13,428 | None |
| Administration of additional new drug or substance into vein, 1 hour or less | 31 | $11,492 | $55 |
| Short return visit (20+ min) | 95 | $9,409 | $57 |
| Administration of chemotherapy into vein, each additional hour | 44 | $7,121 | $25 |
| Injection of additional new drug or substance into vein | 49 | $7,066 | $20 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 67 | $6,066 | $16 |
| Insertion of needle into vein for collection of blood sample | 361 | $5,811 | $3 |
| Injection, heparin sodium, (heparin lock flush), per 10 units | 61 | $5,733 | None |
| Long return visit (40+ min) | 24 | $3,263 | $121 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 17 | $2,557 | $27 |
| Blood test, comprehensive group of blood chemicals | 79 | $2,542 | $14 |
| Injection of drug or substance into vein | 28 | $2,358 | $50 |
| Biopsy of bone marrow | 12 | $1,878 | $144 |
| Infusion into a vein for hydration, 31-60 minutes | 18 | $1,525 | $51 |
| Injection, dexamethasone sodium phosphate, 1 mg | 77 | $1,130 | None |
| Infusion into a vein for hydration, each additional hour | 18 | $504 | $13 |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 15 | $501 | $17 |
| Injection, diphenhydramine hcl, up to 50 mg | 73 | $271 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 26 | $188 | None |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 21 | $114 | None |
| Injection, magnesium sulfate, per 500 mg | 46 | $113 | None |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 25 | $25 | None |
| Injection, potassium chloride, per 2 meq | 12 | $16 | None |
| Injection, lorazepam, 2 mg | 16 | $9 | None |
2013: 53 services
| Return visit (30+ min) | 434 | $241,074 | $87 |
| Injection, sargramostim (gm-csf), 50 mcg | 58 | $201,250 | None |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 298 | $129,236 | $83 |
| Injection, epoetin alfa, (for non-esrd use), 1000 units | 67 | $102,089 | None |
| Administration of chemotherapy into vein, 1 hour or less | 86 | $84,926 | $126 |
| Injection, palonosetron hcl, 25 mcg | 60 | $52,015 | None |
| Injection of drug or substance under skin or into muscle | 141 | $40,795 | $22 |
| Injection, docetaxel, 1 mg | 22 | $39,697 | None |
| Injection, zoledronic acid (zometa), 1 mg | 17 | $35,328 | None |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 111 | $33,927 | $67 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 189 | $32,130 | $161 |
| Zoldedronic acid 1mg | 18 | $25,409 | $135 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 408 | $24,846 | $10 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 114 | $23,931 | $27 |
| Short return visit (20+ min) | 160 | $19,422 | $61 |
| Administration of additional new drug or substance into vein, 1 hour or less | 45 | $16,504 | $63 |
| New patient visit (60+ min) | 88 | $14,294 | $162 |
| Injection, denosumab, 1 mg | 14 | $14,001 | None |
| Injection, fosaprepitant, 1 mg | 13 | $13,193 | None |
| Blood test, comprehensive group of blood chemicals | 264 | $12,070 | $14 |
| Administration of chemotherapy into vein, each additional hour | 58 | $10,456 | $27 |
| Carcinoembryonic antigen (cea) protein level | 158 | $9,479 | $26 |
| Insertion of needle into vein for collection of blood sample | 409 | $7,578 | $3 |
| Injection of additional new drug or substance into vein | 62 | $6,671 | $19 |
| Injection, iron dextran, 50 mg | 27 | $6,578 | None |
| Long return visit (40+ min) | 42 | $6,431 | $119 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 75 | $6,381 | $19 |
| Infusion into a vein for hydration, 31-60 minutes | 41 | $5,342 | $52 |
| Injection, heparin sodium, (heparin lock flush), per 10 units | 66 | $5,322 | None |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 15 | $4,305 | None |
| Administration of additional new drug or substance into vein using push technique | 17 | $3,458 | $55 |
| Biopsy of bone marrow | 19 | $3,424 | $143 |
| Infusion into a vein for hydration, each additional hour | 46 | $2,589 | $14 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 16 | $2,433 | $57 |
| Immunologic analysis for detection of tumor antigen, quantitative; ca 19-9 | 47 | $2,350 | $28 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 14 | $2,253 | $27 |
| Injection of drug or substance into vein | 26 | $1,740 | $51 |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 28 | $1,515 | $16 |
| Injection, dexamethasone sodium phosphate, 1 mg | 107 | $966 | None |
| Injection, carboplatin, 50 mg | 14 | $929 | None |
| Injection, cisplatin, powder or solution, 10 mg | 14 | $765 | None |
| Psa (prostate specific antigen) measurement, total | 11 | $651 | $25 |
| Injection, ondansetron hydrochloride, per 1 mg | 33 | $359 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 99 | $333 | None |
| Injection, fluorouracil, 500 mg | 11 | $254 | None |
| Influenza vaccine, trivalent, split virus, preservative-free, 0.5 ml dosage | 12 | $146 | $12 |
| Administration of influenza virus vaccine | 12 | $118 | $10 |
| Injection, mannitol, 25% in 50 ml | 14 | $102 | None |
| Injection, magnesium sulfate, per 500 mg | 52 | $100 | None |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 24 | $93 | None |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 37 | $33 | None |
| Injection, lorazepam, 2 mg | 16 | $17 | None |
| Injection, potassium chloride, per 2 meq | 21 | $6 | None |
Medicaid work
$73,454 in 2024
Medicaid paid $73,454 for 8,633 billed services this clinician did in 2024, up to 153 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Return visit (30+ min) | 1,765 | $23,641 |
| Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg | 12 | $9,434 |
| Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion of a new drug/substance, up to 1 hour (List separately in addition to code for primary procedure) | 566 | $6,464 |
| Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug | 488 | $6,036 |
| Short return visit (20+ min) | 685 | $5,743 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 633 | $5,692 |
| Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour | 220 | $3,949 |
| Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular | 498 | $2,798 |
| New patient visit (60+ min) | 185 | $2,499 |
| Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 90 | $1,284 |
| Brief emotional/behavioral assessment (eg, depression inventory, attention-deficit/hyperactivity disorder [ADHD] scale), with scoring and documentation, per standardized instrument | 1,013 | $1,205 |
| Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); each additional hour (List separately in addition to code for primary procedure) | 97 | $737 |
| 2024 | 8,633 | 23 | 153 | $73,454 |
| 2023 | 12,150 | 24 | 158 | $148,233 |
| 2022 | 8,802 | 19 | 156 | $156,835 |
| 2021 | 9,508 | 20 | 133 | $153,955 |
| 2020 | 7,260 | 18 | 170 | $122,959 |
| 2019 | 9,932 | 22 | 181 | $189,321 |
| 2018 | 14,143 | 24 | 210 | $388,258 |
See the largest Medicaid services in earlier years
2023
| Return visit (30+ min) | 2,309 | $37,855 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 1,487 | $33,757 |
| Injection, filgrastim-sndz, biosimilar, (zarxio), 1 microgram | 334 | $11,559 |
| Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular | 956 | $10,485 |
| Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion of a new drug/substance, up to 1 hour (List separately in addition to code for primary procedure) | 777 | $9,078 |
| Short return visit (20+ min) | 649 | $6,909 |
| Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug | 591 | $6,677 |
| Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg | 15 | $5,784 |
| Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 242 | $4,675 |
| New patient visit (60+ min) | 156 | $4,345 |
| 1ST HOSP IP/OBS HIGH 75 | 109 | $3,748 |
| Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour | 303 | $3,409 |
2022
| Return visit (30+ min) | 1,869 | $34,438 |
| Injection, dexamethasone sodium phosphate, 1 mg | 488 | $25,758 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 1,047 | $21,785 |
| COLLECTION VENOUS BLOOD VENIPUNCTURE | 1,198 | $17,219 |
| Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular | 729 | $12,269 |
| Short return visit (20+ min) | 688 | $9,560 |
| Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion of a new drug/substance, up to 1 hour (List separately in addition to code for primary procedure) | 533 | $7,409 |
| Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug | 429 | $6,444 |
| New patient visit (60+ min) | 144 | $4,745 |
| Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour | 137 | $4,099 |
| Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count | 441 | $3,625 |
| Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 124 | $2,965 |
2021
| Return visit (30+ min) | 1,664 | $35,304 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 798 | $21,445 |
| Short return visit (20+ min) | 877 | $12,558 |
| Injection, filgrastim-sndz, biosimilar, (zarxio), 1 microgram | 581 | $12,500 |
| Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion of a new drug/substance, up to 1 hour (List separately in addition to code for primary procedure) | 572 | $12,452 |
| Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular | 864 | $11,858 |
| Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour | 341 | $10,804 |
| Injection, magnesium sulfate, per 500 mg | 218 | $7,312 |
| Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug | 444 | $7,154 |
| COLLECTION VENOUS BLOOD VENIPUNCTURE | 928 | $6,850 |
| Palonosetron hcl | 199 | $3,769 |
| Injection, dexamethasone sodium phosphate, 1 mg | 553 | $2,718 |
2020
| Return visit (30+ min) | 2,260 | $58,325 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 737 | $13,755 |
| Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour | 357 | $9,511 |
| Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion of a new drug/substance, up to 1 hour (List separately in addition to code for primary procedure) | 446 | $7,444 |
| Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular | 606 | $5,546 |
| Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug | 420 | $5,308 |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 67 | $3,897 |
| Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count | 428 | $3,897 |
| Injection, dexamethasone sodium phosphate, 1 mg | 371 | $3,647 |
| Short return visit (20+ min) | 243 | $3,266 |
| New patient visit (60+ min) | 61 | $2,341 |
| Injection, diphenhydramine hcl, up to 50 mg | 317 | $1,573 |
2019
| Return visit (30+ min) | 2,642 | $71,202 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 891 | $19,835 |
| Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour | 478 | $18,607 |
| Palonosetron hcl | 175 | $12,551 |
| Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular | 613 | $12,381 |
| Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion of a new drug/substance, up to 1 hour (List separately in addition to code for primary procedure) | 638 | $9,480 |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 240 | $8,934 |
| Injection, magnesium sulfate, per 500 mg | 272 | $5,734 |
| Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug | 645 | $5,209 |
| Injection, filgrastim-sndz, biosimilar, (zarxio), 1 microgram | 37 | $3,428 |
| Chemotherapy administration, intravenous infusion technique; each additional hour (List separately in addition to code for primary procedure) | 255 | $3,345 |
| Chemotherapy administration, intravenous infusion technique; each additional sequential infusion (different substance/drug), up to 1 hour (List separately in addition to code for primary procedure) | 284 | $3,339 |
2018
| Injection, filgrastim-sndz, biosimilar, (zarxio), 1 microgram | 615 | $128,177 |
| Return visit (30+ min) | 3,311 | $74,944 |
| Palonosetron hcl | 400 | $40,513 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 1,223 | $25,751 |
| COLLECTION VENOUS BLOOD VENIPUNCTURE | 691 | $21,916 |
| Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular | 934 | $19,617 |
| Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion of a new drug/substance, up to 1 hour (List separately in addition to code for primary procedure) | 676 | $18,649 |
| Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour | 646 | $13,219 |
| Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug | 708 | $9,863 |
| Injection, dexamethasone sodium phosphate, 1 mg | 604 | $6,161 |
| Short return visit (20+ min) | 179 | $4,631 |
| Chemotherapy administration, intravenous infusion technique; each additional sequential infusion (different substance/drug), up to 1 hour (List separately in addition to code for primary procedure) | 355 | $4,376 |
Drugs they prescribed that Part D paid
$15,643,281
Pharmacies billed $15,643,281 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 2% of their Part D prescriptions (51 of 3,271) in 2024. At or below the middle of the specialty; the typical hematology-oncology clinician is at 5%. Long-acting opioids: 26% of their opioid prescriptions.
1,465 generic and 1,806 brand-name prescriptions · $15,643,281 in drug cost · 55 antibiotic prescriptions to 31 people · 22 antipsychotic prescriptions to people over 65.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Xtandi | 155 | $2,096,177 | $13,524 |
| Kisqali | 113 | $1,731,678 | $15,325 |
| Ibrance | 100 | $1,580,887 | $15,809 |
| Tagrisso | 50 | $969,880 | $19,398 |
| Revlimid | 56 | $968,855 | $17,301 |
See all 59 drugs
| Xtandi | 155 | $2,096,177 | $13,524 |
| Kisqali | 113 | $1,731,678 | $15,325 |
| Ibrance | 100 | $1,580,887 | $15,809 |
| Tagrisso | 50 | $969,880 | $19,398 |
| Revlimid | 56 | $968,855 | $17,301 |
| Somatuline Depot | 70 | $903,009 | $12,900 |
| Lynparza | 70 | $852,503 | $12,179 |
| Procrit | 310 | $815,012 | $2,629 |
| Promacta | 62 | $789,209 | $12,729 |
| Neulasta | 97 | $583,232 | $6,013 |
| Calquence | 32 | $438,721 | $13,710 |
| Doptelet | 24 | $363,347 | $15,139 |
| Erleada | 21 | $301,137 | $14,340 |
| Lupron Depot | 109 | $291,986 | $2,679 |
| Imbruvica | 20 | $287,688 | $14,384 |
| Jakafi | 15 | $267,935 | $17,862 |
| Verzenio | 17 | $240,581 | $14,152 |
| Xgeva | 65 | $204,933 | $3,153 |
| Zarxio | 98 | $185,711 | $1,895 |
| Abiraterone Acetate | 34 | $129,223 | $3,801 |
| Fulvestrant | 125 | $109,660 | $877 |
| Everolimus | 17 | $94,843 | $5,579 |
| Orgovyx | 21 | $73,784 | $3,514 |
| Sancuso | 46 | $71,549 | $1,555 |
| Prolia | 26 | $42,499 | $1,635 |
| Omeprazole-Sodium Bicarbonate | 24 | $33,810 | $1,409 |
| Imatinib Mesylate | 41 | $32,826 | $801 |
| Eliquis | 34 | $24,014 | $706 |
| Firmagon | 11 | $6,584 | $599 |
| Anagrelide | 47 | $4,946 | $105 |
| Exemestane | 37 | $4,163 | $113 |
| Ondansetron Odt | 50 | $1,982 | $40 |
| Letrozole | 130 | $1,822 | $14 |
| Tamoxifen Citrate | 71 | $1,002 | $14 |
| Bortezomib | 16 | $928 | $58 |
| Dexamethasone | 48 | $870 | $18 |
| Anastrozole | 98 | $782 | $8 |
| Clonidine | 13 | $776 | $60 |
| Famciclovir | 19 | $580 | $31 |
| Hydrocodone-Acetaminophen | 27 | $550 | $20 |
| Gabapentin | 28 | $349 | $12 |
| Hydroxyurea | 26 | $264 | $10 |
| Alprazolam | 33 | $157 | $5 |
| Ondansetron | 24 | $127 | $5 |
| Prednisone | 35 | $122 | $3 |
| Sertraline | 18 | $119 | $7 |
| Mirtazapine | 42 | $110 | $3 |
| Pantoprazole | 33 | $105 | $3 |
| Ibuprofen | 17 | $103 | $6 |
| Quetiapine | 11 | $90 | $8 |
| Diphenoxylate-Atropine | 14 | $90 | $6 |
| Dexamethasone Sodium Phosphate | 20 | $60 | $3 |
| Sulfamethoxazole-Trimethoprim | 22 | $59 | $3 |
| Levofloxacin | 11 | $29 | $3 |
| Methadone | 12 | $27 | $2 |
| Sodium Chloride | 13 | $26 | $2 |
| Diphenhydramine | 20 | $24 | $1 |
| Famotidine | 12 | $15 | $1 |
| Furosemide | 12 | $12 | $1 |
Year by year
| 2024 | 3,271 | 407 | 2% (51) | 55% | $15,643,281 |
| 2023 | 6,335 | 438 | 1% (41) | None | $23,642,935 |
| 2022 | 6,751 | 493 | 1% (44) | 42% | $20,560,177 |
| 2021 | 6,090 | 457 | 2% (133) | 45% | $16,906,012 |
| 2020 | 4,163 | 413 | 3% (128) | None | $12,120,134 |
| 2019 | 3,752 | 417 | 4% (149) | 52% | $11,575,159 |
| 2018 | 3,796 | 396 | 5% (193) | None | $9,152,995 |
| 2017 | 2,995 | 380 | 4% (125) | None | $5,429,182 |
| 2016 | 2,749 | 341 | 5% (131) | None | $4,899,788 |
| 2015 | 2,552 | 301 | 5% (127) | 43% | $4,137,637 |
| 2014 | 2,577 | 262 | 6% (149) | 38% | $2,973,817 |
| 2013 | 2,601 | 263 | 6% (152) | 42% | $3,335,475 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 94 drugs
| Octagam | Immune globulin | 525 | $2,843,000 | $5,415 |
| Ibrance | None | 135 | $2,269,401 | $16,810 |
| Xtandi | None | 103 | $1,524,131 | $14,797 |
| Kisqali | None | 65 | $1,136,317 | $17,482 |
| Procrit | None | 288 | $1,033,596 | $3,589 |
| Lynparza | None | 56 | $824,198 | $14,718 |
| Keytruda | None | 67 | $801,124 | $11,957 |
| Tagrisso | None | 43 | $764,404 | $17,777 |
| Erleada | None | 43 | $651,625 | $15,154 |
| Reblozyl | None | 21 | $647,400 | $30,829 |
| Neulasta | None | 83 | $626,140 | $7,544 |
| Kyprolis | None | 69 | $605,350 | $8,773 |
| Inlyta | None | 14 | $551,448 | $39,389 |
| Neulasta Onpro | None | 68 | $475,474 | $6,992 |
| Mvasi | None | 59 | $472,900 | $8,015 |
| Darzalex Faspro | None | 15 | $453,160 | $30,211 |
| Tecentriq | None | 40 | $442,142 | $11,054 |
| Revlimid | None | 22 | $415,121 | $18,869 |
| Somatuline Depot | None | 39 | $404,608 | $10,375 |
| Imbruvica | None | 24 | $385,080 | $16,045 |
| Promacta | None | 33 | $383,623 | $11,625 |
| Lupron Depot | None | 134 | $347,424 | $2,593 |
| Zarxio | None | 200 | $339,018 | $1,695 |
| Jakafi | None | 15 | $315,062 | $21,004 |
| Rubraca | None | 18 | $271,549 | $15,086 |
| Opdivo | None | 17 | $264,506 | $15,559 |
| Libtayo | None | 25 | $259,627 | $10,385 |
| Truxima | None | 26 | $253,151 | $9,737 |
| Verzenio | None | 13 | $207,914 | $15,993 |
| Doptelet | None | 15 | $187,137 | $12,476 |
| Privigen | Immune globulin | 29 | $184,747 | $6,371 |
| Fulvestrant | None | 104 | $157,397 | $1,513 |
| Venclexta | None | 16 | $155,858 | $9,741 |
| Tavalisse | None | 11 | $153,017 | $13,911 |
| Everolimus | None | 11 | $152,342 | $13,849 |
| Ninlaro | None | 12 | $147,800 | $12,317 |
| Omeprazole-Sodium Bicarbonate | None | 27 | $138,254 | $5,121 |
| Halaven | None | 11 | $82,189 | $7,472 |
| Prolia | None | 48 | $81,312 | $1,694 |
| Creon | None | 17 | $77,078 | $4,534 |
| Irinotecan | None | 41 | $74,331 | $1,813 |
| Sancuso | None | 52 | $70,825 | $1,362 |
| Eliquis | None | 95 | $69,552 | $732 |
| Imatinib Mesylate | None | 32 | $65,329 | $2,042 |
| Doxorubicin Hcl Liposome | None | 25 | $56,343 | $2,254 |
| Xgeva | None | 17 | $56,096 | $3,300 |
| Bortezomib | None | 37 | $40,644 | $1,098 |
| Anagrelide | None | 42 | $24,274 | $578 |
| Oxaliplatin | None | 37 | $23,459 | $634 |
| Zoledronic Acid | None | 105 | $19,692 | $188 |
| Palonosetron | None | 173 | $17,471 | $101 |
| Cyclophosphamide | None | 20 | $13,575 | $679 |
| Linzess | None | 11 | $10,189 | $926 |
| Exemestane | None | 47 | $8,209 | $175 |
| Gemcitabine | None | 11 | $7,570 | $688 |
| Deferasirox | None | 11 | $6,845 | $622 |
| Fosaprepitant Dimeglumine | None | 24 | $6,585 | $274 |
| Sucralfate | None | 24 | $3,591 | $150 |
| Tamoxifen Citrate | None | 116 | $3,088 | $27 |
| Leucovorin | None | 15 | $2,964 | $198 |
| Dexamethasone Sodium Phosphate | None | 614 | $2,824 | $5 |
| Anastrozole | None | 92 | $2,602 | $28 |
| Carboplatin | None | 53 | $2,588 | $49 |
| Letrozole | None | 142 | $2,264 | $16 |
| Paclitaxel | None | 24 | $2,219 | $92 |
| Ondansetron Odt | None | 80 | $1,960 | $24 |
| Diphenhydramine | None | 601 | $1,529 | $3 |
| Pantoprazole | None | 67 | $1,498 | $22 |
| Fluorouracil | None | 15 | $1,174 | $78 |
| Hydrocodone-Acetaminophen | None | 23 | $961 | $42 |
| Dexamethasone | None | 39 | $892 | $23 |
| Etoposide | None | 14 | $757 | $54 |
| Hydroxyurea | None | 25 | $662 | $26 |
| Gabapentin | None | 27 | $595 | $22 |
| Valsartan | None | 14 | $589 | $42 |
| Famotidine | None | 215 | $415 | $2 |
| Mirtazapine | None | 32 | $407 | $13 |
| Atropine Sulfate | None | 20 | $328 | $16 |
| Dicyclomine | None | 18 | $304 | $17 |
| Sertraline | None | 14 | $230 | $16 |
| Ondansetron | None | 54 | $228 | $4 |
| Alprazolam | None | 33 | $209 | $6 |
| Metoclopramide | None | 12 | $156 | $13 |
| Ibuprofen | None | 13 | $154 | $12 |
| Levetiracetam | None | 16 | $153 | $10 |
| Prednisone | None | 20 | $137 | $7 |
| Alendronate | None | 12 | $131 | $11 |
| Levofloxacin | None | 12 | $123 | $10 |
| Mupirocin | None | 12 | $121 | $10 |
| Methadone | None | 11 | $81 | $7 |
| Potassium Chloride | None | 15 | $73 | $5 |
| Azithromycin | None | 11 | $65 | $6 |
| Dexamethasone Sodium Phosphate | None | 11 | $63 | $6 |
| Furosemide | None | 13 | $61 | $5 |
2022: 99 drugs
| Octagam | Immune globulin | 434 | $2,117,829 | $4,880 |
| Ibrance | None | 121 | $1,844,747 | $15,246 |
| Xtandi | None | 112 | $1,556,202 | $13,895 |
| Neulasta | None | 166 | $1,338,189 | $8,061 |
| Procrit | None | 305 | $1,222,061 | $4,007 |
| Revlimid | None | 44 | $828,710 | $18,834 |
| Tecentriq | None | 71 | $755,565 | $10,642 |
| Reblozyl | None | 29 | $721,617 | $24,883 |
| Cabometyx | None | 28 | $695,563 | $24,842 |
| Keytruda | None | 55 | $616,753 | $11,214 |
| Mvasi | None | 69 | $586,527 | $8,500 |
| Tagrisso | None | 33 | $577,974 | $17,514 |
| Truxima | None | 49 | $499,816 | $10,200 |
| Kisqali | None | 29 | $464,274 | $16,009 |
| Kyprolis | None | 86 | $427,359 | $4,969 |
| Erleada | None | 26 | $380,631 | $14,640 |
| Lupron Depot | None | 150 | $376,108 | $2,507 |
| Imbruvica | None | 23 | $363,671 | $15,812 |
| Rubraca | None | 19 | $319,652 | $16,824 |
| Jakafi | None | 18 | $315,474 | $17,526 |
| Verzenio | None | 20 | $299,420 | $14,971 |
| Lenvima | None | 11 | $237,810 | $21,619 |
| Ninlaro | None | 19 | $223,196 | $11,747 |
| Opdivo | None | 15 | $222,798 | $14,853 |
| Zarxio | None | 65 | $210,981 | $3,246 |
| Fulvestrant | None | 119 | $192,523 | $1,618 |
| Privigen | Immune globulin | 24 | $179,732 | $7,489 |
| Lynparza | None | 14 | $177,949 | $12,711 |
| Tavalisse | None | 13 | $171,139 | $13,165 |
| Somatuline Depot | None | 16 | $163,502 | $10,219 |
| Zykadia | None | 12 | $136,436 | $11,370 |
| Venclexta | None | 12 | $129,577 | $10,798 |
| Velcade | None | 28 | $118,938 | $4,248 |
| Darzalex | None | 13 | $105,952 | $8,150 |
| Creon | None | 32 | $97,232 | $3,038 |
| Prolia | None | 59 | $90,594 | $1,535 |
| Halaven | None | 14 | $85,776 | $6,127 |
| Irinotecan | None | 46 | $85,752 | $1,864 |
| Kanjinti | None | 24 | $84,193 | $3,508 |
| Eliquis | None | 123 | $77,504 | $630 |
| Pemetrexed Disodium | None | 18 | $77,020 | $4,279 |
| Xgeva | None | 24 | $69,322 | $2,888 |
| Abiraterone Acetate | None | 13 | $64,431 | $4,956 |
| Docetaxel | None | 25 | $53,468 | $2,139 |
| Sancuso | None | 48 | $50,179 | $1,045 |
| Imatinib Mesylate | None | 38 | $42,673 | $1,123 |
| Anagrelide | None | 64 | $38,001 | $594 |
| Bortezomib | None | 25 | $29,823 | $1,193 |
| Cyclophosphamide | None | 37 | $28,252 | $764 |
| Palonosetron | None | 225 | $27,191 | $121 |
| Fosaprepitant Dimeglumine | None | 72 | $19,535 | $271 |
| Oxaliplatin | None | 28 | $13,899 | $496 |
| Zoledronic Acid | None | 95 | $13,046 | $137 |
| Exemestane | None | 78 | $10,679 | $137 |
| Linzess | None | 18 | $10,423 | $579 |
| Deferasirox | None | 16 | $9,367 | $585 |
| Xarelto | None | 13 | $7,446 | $573 |
| Paclitaxel | None | 51 | $4,773 | $94 |
| Tamoxifen Citrate | None | 227 | $4,253 | $19 |
| Carboplatin | None | 64 | $2,749 | $43 |
| Anastrozole | None | 168 | $2,637 | $16 |
| Cisplatin | None | 38 | $2,635 | $69 |
| Ondansetron Odt | None | 84 | $2,393 | $28 |
| Sucralfate | None | 21 | $2,379 | $113 |
| Dexamethasone Sodium Phosphate | None | 541 | $2,269 | $4 |
| Letrozole | None | 125 | $2,227 | $18 |
| Leucovorin | None | 11 | $2,039 | $185 |
| Dexamethasone | None | 66 | $1,919 | $29 |
| Diphenhydramine | None | 501 | $1,767 | $4 |
| Doxorubicin | None | 20 | $1,488 | $74 |
| Etoposide | None | 25 | $1,316 | $53 |
| Ibandronate | None | 23 | $1,288 | $56 |
| Hydroxyurea | None | 55 | $1,250 | $23 |
| Sps | None | 13 | $1,185 | $91 |
| Gabapentin | None | 57 | $934 | $16 |
| Hydrocodone-Acetaminophen | None | 22 | $865 | $39 |
| Pantoprazole | None | 86 | $722 | $8 |
| Ondansetron | None | 20 | $714 | $36 |
| Famotidine | None | 237 | $486 | $2 |
| Mirtazapine | None | 44 | $400 | $9 |
| Atropine Sulfate | None | 23 | $357 | $16 |
| Valsartan | None | 18 | $341 | $19 |
| Alprazolam | None | 35 | $338 | $10 |
| Ondansetron | None | 49 | $219 | $4 |
| Potassium Chloride | None | 17 | $215 | $13 |
| Prednisone | None | 52 | $201 | $4 |
| Vincristine Sulfate | None | 18 | $191 | $11 |
| Alendronate | None | 27 | $182 | $7 |
| Azithromycin | None | 25 | $161 | $6 |
| Methadone | None | 11 | $145 | $13 |
| Levofloxacin | None | 26 | $139 | $5 |
| Tamsulosin | None | 14 | $136 | $10 |
| Sertraline | None | 14 | $112 | $8 |
| Methylprednisolone | None | 14 | $111 | $8 |
| Losartan | None | 21 | $106 | $5 |
| Clonidine | None | 12 | $76 | $6 |
| Ibuprofen | None | 13 | $63 | $5 |
| Metoclopramide | None | 14 | $60 | $4 |
| Furosemide | None | 14 | $27 | $2 |
2021: 105 drugs
| Octagam | Immune globulin | 466 | $1,646,830 | $3,534 |
| Ibrance | None | 117 | $1,645,277 | $14,062 |
| Procrit | None | 315 | $1,227,065 | $3,895 |
| Revlimid | None | 64 | $1,170,265 | $18,285 |
| Xtandi | None | 71 | $919,227 | $12,947 |
| Verzenio | None | 43 | $601,050 | $13,978 |
| Reblozyl | None | 22 | $544,980 | $24,772 |
| Keytruda | None | 50 | $533,545 | $10,671 |
| Kisqali | None | 30 | $445,794 | $14,860 |
| Velcade | None | 77 | $429,555 | $5,579 |
| Tecentriq | None | 39 | $392,017 | $10,052 |
| Zarxio | None | 114 | $367,262 | $3,222 |
| Inlyta | None | 12 | $354,088 | $29,507 |
| Rubraca | None | 24 | $348,804 | $14,534 |
| Imbruvica | None | 25 | $348,147 | $13,926 |
| Lupron Depot | None | 156 | $300,104 | $1,924 |
| Mvasi | None | 50 | $288,872 | $5,777 |
| Kyprolis | None | 55 | $284,581 | $5,174 |
| Lenvima | None | 13 | $283,648 | $21,819 |
| Afinitor | None | 14 | $239,584 | $17,113 |
| Lynparza | None | 18 | $238,082 | $13,227 |
| Tagrisso | None | 14 | $234,428 | $16,745 |
| Tukysa | None | 11 | $228,321 | $20,756 |
| Truxima | None | 26 | $188,419 | $7,247 |
| Tavalisse | None | 12 | $155,900 | $12,992 |
| Enhertu | None | 15 | $150,051 | $10,003 |
| Fulphila | None | 32 | $140,287 | $4,384 |
| Ninlaro | None | 12 | $138,286 | $11,524 |
| Fulvestrant | None | 74 | $118,271 | $1,598 |
| Zirabev | None | 25 | $114,060 | $4,562 |
| Deferasirox | None | 12 | $112,698 | $9,391 |
| Somatuline Depot | None | 11 | $105,876 | $9,625 |
| Kanjinti | None | 27 | $104,757 | $3,880 |
| Darzalex | None | 16 | $100,848 | $6,303 |
| Privigen | Immune globulin | 11 | $96,679 | $8,789 |
| Xgeva | None | 30 | $78,894 | $2,630 |
| Prolia | None | 52 | $72,924 | $1,402 |
| Avastin | None | 19 | $65,454 | $3,445 |
| Eliquis | None | 94 | $57,000 | $606 |
| Abiraterone Acetate | None | 13 | $53,966 | $4,151 |
| Gammagard Liquid | Immune globulin | 12 | $46,140 | $3,845 |
| Doxorubicin Hcl Liposome | None | 16 | $37,607 | $2,350 |
| Retacrit | None | 18 | $29,674 | $1,649 |
| Imatinib Mesylate | None | 17 | $27,711 | $1,630 |
| Zoledronic Acid | None | 118 | $24,546 | $208 |
| Anagrelide | None | 51 | $23,999 | $471 |
| Sancuso | None | 33 | $23,545 | $713 |
| Palonosetron | None | 90 | $23,018 | $256 |
| Irinotecan | None | 38 | $15,482 | $407 |
| Creon | None | 12 | $12,793 | $1,066 |
| Xarelto | None | 23 | $11,697 | $509 |
| Exemestane | None | 71 | $7,969 | $112 |
| Fosaprepitant Dimeglumine | None | 19 | $5,064 | $267 |
| Oxaliplatin | None | 23 | $4,770 | $207 |
| Tamoxifen Citrate | None | 215 | $3,895 | $18 |
| Letrozole | None | 133 | $2,964 | $22 |
| Anastrozole | None | 202 | $2,654 | $13 |
| Hydroxyurea | None | 74 | $2,098 | $28 |
| Gemcitabine | None | 25 | $1,964 | $79 |
| Leucovorin | None | 14 | $1,962 | $140 |
| Dexamethasone | None | 64 | $1,793 | $28 |
| Hydrocodone-Acetaminophen | None | 67 | $1,750 | $26 |
| Pantoprazole | None | 128 | $1,545 | $12 |
| Diclofenac | None | 16 | $1,477 | $92 |
| Ondansetron Odt | None | 62 | $1,386 | $22 |
| Dexamethasone Sodium Phosphate | None | 321 | $1,234 | $4 |
| Cisplatin | None | 24 | $1,028 | $43 |
| Carboplatin | None | 27 | $772 | $29 |
| Gabapentin | None | 65 | $752 | $12 |
| Fluorouracil | None | 18 | $718 | $40 |
| Ondansetron | None | 40 | $715 | $18 |
| Ibandronate | None | 18 | $694 | $39 |
| Diphenhydramine | None | 290 | $627 | $2 |
| Mirtazapine | None | 52 | $621 | $12 |
| Valsartan-Hydrochlorothiazide | None | 11 | $607 | $55 |
| Sps | None | 14 | $562 | $40 |
| Calcium Gluconate | None | 14 | $554 | $40 |
| Alprazolam | None | 45 | $529 | $12 |
| Fluconazole | None | 12 | $513 | $43 |
| Morphine Sulfate Er | None | 15 | $460 | $31 |
| Oxycodone | None | 11 | $455 | $41 |
| Levothyroxine | None | 25 | $434 | $17 |
| Paclitaxel | None | 14 | $388 | $28 |
| Famotidine | None | 174 | $384 | $2 |
| Diphenoxylate-Atropine | None | 15 | $283 | $19 |
| Magnesium Sulfate | None | 71 | $264 | $4 |
| Bicalutamide | None | 19 | $247 | $13 |
| Loperamide | None | 12 | $244 | $20 |
| Ondansetron | None | 48 | $223 | $5 |
| Metoclopramide | None | 12 | $207 | $17 |
| Sulfamethoxazole-Trimethoprim | None | 19 | $199 | $10 |
| Atropine Sulfate | None | 12 | $181 | $15 |
| Prednisone | None | 46 | $166 | $4 |
| Azithromycin | None | 22 | $158 | $7 |
| Mannitol | None | 19 | $158 | $8 |
| Acyclovir | None | 17 | $158 | $9 |
| Meclizine | None | 21 | $155 | $7 |
| Sertraline | None | 20 | $144 | $7 |
| Methadone | None | 12 | $141 | $12 |
| Potassium Chloride | None | 29 | $137 | $5 |
| Omeprazole | None | 18 | $123 | $7 |
| Alendronate | None | 15 | $121 | $8 |
| Clonidine | None | 22 | $76 | $3 |
| Levofloxacin | None | 11 | $48 | $4 |
| Furosemide | None | 20 | $31 | $2 |
2020: 86 drugs
| Ibrance | None | 117 | $1,542,808 | $13,186 |
| Procrit | None | 343 | $1,395,901 | $4,070 |
| Revlimid | None | 46 | $786,585 | $17,100 |
| Privigen | Immune globulin | 219 | $758,518 | $3,464 |
| Kisqali | None | 39 | $513,183 | $13,159 |
| Zarxio | None | 140 | $453,092 | $3,236 |
| Kyprolis | None | 28 | $422,010 | $15,072 |
| Reblozyl | None | 21 | $415,019 | $19,763 |
| Verzenio | None | 30 | $407,789 | $13,593 |
| Xtandi | None | 22 | $275,003 | $12,500 |
| Zytiga | None | 23 | $258,799 | $11,252 |
| Darzalex | None | 22 | $246,053 | $11,184 |
| Tagrisso | None | 15 | $237,853 | $15,857 |
| Pomalyst | None | 12 | $231,700 | $19,308 |
| Promacta | None | 23 | $224,474 | $9,760 |
| Lynparza | None | 21 | $223,549 | $10,645 |
| Alecensa | None | 14 | $216,633 | $15,474 |
| Tavalisse | None | 12 | $192,611 | $16,051 |
| Rubraca | None | 15 | $178,252 | $11,883 |
| Imbruvica | None | 12 | $162,447 | $13,537 |
| Deferasirox | None | 18 | $143,047 | $7,947 |
| Lonsurf | None | 11 | $141,452 | $12,859 |
| Lupron Depot | None | 70 | $138,376 | $1,977 |
| Sutent | None | 15 | $114,894 | $7,660 |
| Xgeva | None | 43 | $105,328 | $2,449 |
| Somatuline Depot | None | 11 | $99,529 | $9,048 |
| Velcade | None | 22 | $95,849 | $4,357 |
| Abiraterone Acetate | None | 15 | $91,939 | $6,129 |
| Fulvestrant | None | 45 | $89,073 | $1,979 |
| Retacrit | None | 45 | $82,656 | $1,837 |
| Sancuso | None | 66 | $62,555 | $948 |
| Fulphila | None | 13 | $56,571 | $4,352 |
| Gammagard Liquid | Immune globulin | 14 | $49,451 | $3,532 |
| Eliquis | None | 69 | $35,667 | $517 |
| Prolia | None | 23 | $29,940 | $1,302 |
| Imatinib Mesylate | None | 12 | $24,145 | $2,012 |
| Xarelto | None | 24 | $12,589 | $525 |
| Zoledronic Acid | None | 62 | $12,569 | $203 |
| Anagrelide | None | 27 | $11,956 | $443 |
| Exemestane | None | 32 | $5,704 | $178 |
| Tamoxifen Citrate | None | 171 | $5,180 | $30 |
| Anastrozole | None | 182 | $2,539 | $14 |
| Letrozole | None | 145 | $2,104 | $15 |
| Duloxetine | None | 22 | $1,879 | $85 |
| Hydrocodone-Acetaminophen | None | 76 | $1,758 | $23 |
| Irinotecan | None | 11 | $1,755 | $160 |
| Ondansetron | None | 81 | $1,548 | $19 |
| Sodium Chloride | None | 36 | $1,291 | $36 |
| Hydroxyurea | None | 61 | $1,279 | $21 |
| Sucralfate | None | 14 | $1,108 | $79 |
| Ondansetron Odt | None | 45 | $1,088 | $24 |
| Sodium Polystyrene Sulfonate | None | 13 | $903 | $69 |
| Pantoprazole | None | 97 | $856 | $9 |
| Nitrofurantoin Mono-Macro | None | 13 | $833 | $64 |
| Dexamethasone | None | 35 | $822 | $23 |
| Albuterol Sulfate Hfa | None | 16 | $701 | $44 |
| Bicalutamide | None | 18 | $698 | $39 |
| Mupirocin | None | 23 | $621 | $27 |
| Diphenoxylate-Atropine | None | 32 | $603 | $19 |
| Gabapentin | None | 43 | $443 | $10 |
| Morphine Sulfate Er | None | 13 | $399 | $31 |
| Alprazolam | None | 35 | $376 | $11 |
| Mirtazapine | None | 48 | $360 | $8 |
| Levothyroxine | None | 15 | $339 | $23 |
| Prochlorperazine Maleate | None | 18 | $300 | $17 |
| Acyclovir | None | 27 | $280 | $10 |
| Sertraline | None | 32 | $278 | $9 |
| Prednisone | None | 58 | $228 | $4 |
| Methotrexate | None | 11 | $198 | $18 |
| Meclizine | None | 26 | $187 | $7 |
| Cephalexin | None | 25 | $169 | $7 |
| Diphenhydramine | None | 47 | $141 | $3 |
| Methylprednisolone | None | 12 | $136 | $11 |
| Dexamethasone Sodium Phosphate | None | 38 | $134 | $4 |
| Azithromycin | None | 20 | $126 | $6 |
| Potassium Chloride | None | 20 | $126 | $6 |
| Sulfamethoxazole-Trimethoprim | None | 26 | $124 | $5 |
| Levofloxacin | None | 21 | $118 | $6 |
| Omeprazole | None | 18 | $108 | $6 |
| Ciprofloxacin | None | 12 | $98 | $8 |
| Triamcinolone Acetonide | None | 13 | $77 | $6 |
| Metoclopramide | None | 11 | $59 | $5 |
| Ibuprofen | None | 13 | $55 | $4 |
| Famotidine | None | 26 | $52 | $2 |
| Methadone | None | 12 | $48 | $4 |
| Furosemide | None | 12 | $29 | $2 |
2019: 78 drugs
| Ibrance | None | 105 | $1,301,375 | $12,394 |
| Procrit | None | 287 | $1,181,592 | $4,117 |
| Privigen | Immune globulin | 230 | $949,465 | $4,128 |
| Avastin | None | 69 | $696,114 | $10,089 |
| Revlimid | None | 42 | $653,104 | $15,550 |
| Zarxio | None | 165 | $532,361 | $3,226 |
| Kyprolis | None | 36 | $486,253 | $13,507 |
| Keytruda | None | 45 | $446,114 | $9,914 |
| Pomalyst | None | 19 | $339,159 | $17,850 |
| Xtandi | None | 25 | $306,466 | $12,259 |
| Zytiga | None | 20 | $220,216 | $11,011 |
| Verzenio | None | 17 | $209,898 | $12,347 |
| Rubraca | None | 18 | $205,810 | $11,434 |
| Tagrisso | None | 13 | $201,001 | $15,462 |
| Mekinist | None | 18 | $200,167 | $11,120 |
| Tafinlar | None | 16 | $189,073 | $11,817 |
| Jadenu | None | 14 | $182,810 | $13,058 |
| Lynparza | None | 15 | $169,446 | $11,296 |
| Opdivo | None | 13 | $169,048 | $13,004 |
| Xgeva | None | 63 | $150,293 | $2,386 |
| Tecentriq | None | 15 | $143,110 | $9,541 |
| Sutent | None | 21 | $141,298 | $6,728 |
| Bosulif | None | 12 | $136,889 | $11,407 |
| Fulphila | None | 30 | $130,351 | $4,345 |
| Ninlaro | None | 12 | $125,992 | $10,499 |
| Erbitux | None | 16 | $121,251 | $7,578 |
| Tarceva | None | 14 | $115,905 | $8,279 |
| Sancuso | None | 80 | $88,442 | $1,106 |
| Velcade | None | 13 | $75,581 | $5,814 |
| Lupron Depot | None | 37 | $75,537 | $2,042 |
| Abiraterone Acetate | None | 12 | $73,493 | $6,124 |
| Cyramza | None | 12 | $67,740 | $5,645 |
| Gammagard Liquid | Immune globulin | 13 | $62,278 | $4,791 |
| Faslodex | None | 22 | $58,970 | $2,680 |
| Imatinib Mesylate | None | 15 | $41,269 | $2,751 |
| Eliquis | None | 34 | $17,331 | $510 |
| Anagrelide | None | 34 | $15,867 | $467 |
| Oxycontin | None | 16 | $14,626 | $914 |
| Aromasin | None | 11 | $11,656 | $1,060 |
| Exemestane | None | 24 | $8,605 | $359 |
| Xarelto | None | 14 | $6,344 | $453 |
| Tamoxifen Citrate | None | 177 | $5,227 | $30 |
| Letrozole | None | 151 | $2,748 | $18 |
| Anastrozole | None | 152 | $2,224 | $15 |
| Hydrocodone-Acetaminophen | None | 77 | $2,004 | $26 |
| Hydroxyurea | None | 73 | $1,746 | $24 |
| Narcan | None | 12 | $1,562 | $130 |
| Ondansetron | None | 63 | $1,260 | $20 |
| Clindamycin Phosphate | None | 14 | $1,010 | $72 |
| Dexamethasone | None | 43 | $814 | $19 |
| Gabapentin | None | 73 | $757 | $10 |
| Ondansetron Odt | None | 38 | $704 | $19 |
| Pantoprazole | None | 80 | $576 | $7 |
| Diphenoxylate-Atropine | None | 30 | $546 | $18 |
| Methotrexate | None | 13 | $389 | $30 |
| Morphine Sulfate Er | None | 15 | $384 | $26 |
| Sucralfate | None | 12 | $383 | $32 |
| Prednisone | None | 54 | $354 | $7 |
| Mirtazapine | None | 28 | $290 | $10 |
| Sodium Chloride | None | 20 | $286 | $14 |
| Omeprazole | None | 36 | $284 | $8 |
| Azithromycin | None | 35 | $282 | $8 |
| Sertraline | None | 45 | $260 | $6 |
| Levofloxacin | None | 38 | $223 | $6 |
| Potassium Chloride | None | 23 | $219 | $10 |
| Bicalutamide | None | 12 | $193 | $16 |
| Prochlorperazine Maleate | None | 14 | $190 | $14 |
| Acyclovir | None | 20 | $176 | $9 |
| Alprazolam | None | 27 | $173 | $6 |
| Methylprednisolone | None | 11 | $167 | $15 |
| Mupirocin | None | 13 | $150 | $12 |
| Ibuprofen | None | 18 | $126 | $7 |
| Alendronate | None | 15 | $97 | $6 |
| Cephalexin | None | 11 | $94 | $9 |
| Metoclopramide | None | 14 | $91 | $7 |
| Methadone | None | 13 | $79 | $6 |
| Lorazepam | None | 14 | $59 | $4 |
| Furosemide | None | 20 | $55 | $3 |
2018: 73 drugs
| Ibrance | None | 92 | $1,088,468 | $11,831 |
| Procrit | None | 271 | $984,883 | $3,634 |
| Revlimid | None | 52 | $762,062 | $14,655 |
| Avastin | None | 61 | $494,194 | $8,102 |
| Opdivo | None | 34 | $415,503 | $12,221 |
| Zarxio | None | 114 | $381,801 | $3,349 |
| Privigen | Immune globulin | 77 | $317,553 | $4,124 |
| Herceptin | None | 81 | $294,576 | $3,637 |
| Pomalyst | None | 18 | $283,609 | $15,756 |
| Ninlaro | None | 27 | $280,258 | $10,380 |
| Zytiga | None | 25 | $254,585 | $10,183 |
| Keytruda | None | 27 | $253,786 | $9,399 |
| Xtandi | None | 23 | $253,111 | $11,005 |
| Perjeta | None | 43 | $235,110 | $5,468 |
| Velcade | None | 31 | $199,114 | $6,423 |
| Rituxan | None | 16 | $195,104 | $12,194 |
| Xalkori | None | 11 | $189,779 | $17,253 |
| Tagrisso | None | 11 | $161,691 | $14,699 |
| Verzenio | None | 12 | $137,956 | $11,496 |
| Sutent | None | 21 | $131,853 | $6,279 |
| Bosulif | None | 12 | $130,544 | $10,879 |
| Tarceva | None | 15 | $123,146 | $8,210 |
| Sancuso | None | 103 | $105,956 | $1,029 |
| Imatinib Mesylate | None | 21 | $81,293 | $3,871 |
| Xgeva | None | 25 | $52,438 | $2,098 |
| Alimta | None | 13 | $37,767 | $2,905 |
| Anagrelide | None | 27 | $22,278 | $825 |
| Oxycontin | None | 18 | $17,460 | $970 |
| Exemestane | None | 41 | $14,267 | $348 |
| Eliquis | None | 30 | $12,683 | $423 |
| Pradaxa | None | 19 | $7,911 | $416 |
| Tamoxifen Citrate | None | 243 | $6,308 | $26 |
| Hydrocodone-Acetaminophen | None | 97 | $2,682 | $28 |
| Anastrozole | None | 187 | $2,635 | $14 |
| Letrozole | None | 127 | $2,161 | $17 |
| Hydroxyurea | None | 81 | $1,828 | $23 |
| Dexamethasone | None | 70 | $1,639 | $23 |
| Ondansetron | None | 48 | $1,076 | $22 |
| Ibandronate | None | 19 | $1,016 | $53 |
| Sodium Chloride | None | 32 | $836 | $26 |
| Pantoprazole | None | 142 | $832 | $6 |
| Esomeprazole Magnesium | None | 13 | $821 | $63 |
| Ondansetron Odt | None | 48 | $777 | $16 |
| Ventolin Hfa | None | 13 | $712 | $55 |
| Potassium Chloride | None | 31 | $703 | $23 |
| Diphenoxylate-Atropine | None | 27 | $488 | $18 |
| Levofloxacin | None | 44 | $463 | $11 |
| Gabapentin | None | 50 | $445 | $9 |
| Morphine Sulfate Er | None | 14 | $434 | $31 |
| Sucralfate | None | 16 | $434 | $27 |
| Prochlorperazine Maleate | None | 45 | $363 | $8 |
| Methotrexate | None | 12 | $352 | $29 |
| Metoprolol | None | 11 | $346 | $31 |
| Oxycodone | None | 13 | $341 | $26 |
| Alprazolam | None | 42 | $336 | $8 |
| Bicalutamide | None | 14 | $313 | $22 |
| Alendronate | None | 41 | $296 | $7 |
| Prednisone | None | 42 | $257 | $6 |
| Omeprazole | None | 31 | $251 | $8 |
| Azithromycin | None | 29 | $180 | $6 |
| Levetiracetam | None | 13 | $166 | $13 |
| Sertraline | None | 31 | $155 | $5 |
| Metoclopramide | None | 18 | $152 | $8 |
| Montelukast | None | 23 | $129 | $6 |
| Dexamethasone Sodium Phosphate | None | 21 | $89 | $4 |
| Ibuprofen | None | 14 | $80 | $6 |
| Methadone | None | 12 | $77 | $6 |
| Ciprofloxacin | None | 14 | $73 | $5 |
| Furosemide | None | 20 | $52 | $3 |
| Lorazepam | None | 15 | $49 | $3 |
| Amoxicillin | None | 11 | $40 | $4 |
| Diphenhydramine | None | 13 | $32 | $2 |
| Famotidine | None | 11 | $25 | $2 |
2017: 60 drugs
| Procrit | 278 | $1,002,940 | $3,608 |
| Revlimid | 60 | $777,717 | $12,962 |
| Ibrance | 47 | $537,706 | $11,441 |
| Pomalyst | 21 | $313,547 | $14,931 |
| Zytiga | 31 | $281,863 | $9,092 |
| Herceptin | 64 | $278,282 | $4,348 |
| Ninlaro | 23 | $220,842 | $9,602 |
| Opdivo | 22 | $173,079 | $7,867 |
| Zarxio | 56 | $169,455 | $3,026 |
| Xtandi | 12 | $122,473 | $10,206 |
| Tarceva | 16 | $122,261 | $7,641 |
| Perjeta | 20 | $100,841 | $5,042 |
| Gilotrif | 12 | $90,001 | $7,500 |
| Sutent | 13 | $79,268 | $6,098 |
| Sancuso | 46 | $55,473 | $1,206 |
| Sandostatin Lar Depot | 13 | $50,422 | $3,879 |
| Neupogen | 12 | $45,575 | $3,798 |
| Exemestane | 53 | $20,602 | $389 |
| Pradaxa | 32 | $13,907 | $435 |
| Aromasin | 12 | $11,454 | $954 |
| Anagrelide | 18 | $10,626 | $590 |
| Xarelto | 22 | $8,536 | $388 |
| Oxycontin | 12 | $7,480 | $623 |
| Tamoxifen Citrate | 252 | $6,121 | $24 |
| Eliquis | 15 | $5,904 | $394 |
| Dexilant | 12 | $3,124 | $260 |
| Nexium | 11 | $2,743 | $249 |
| Anastrozole | 201 | $2,392 | $12 |
| Hydrocodone-Acetaminophen | 71 | $2,206 | $31 |
| Ibandronate | 48 | $2,155 | $45 |
| Hydroxyurea | 62 | $1,279 | $21 |
| Letrozole | 96 | $959 | $10 |
| Dexamethasone | 67 | $870 | $13 |
| Esomeprazole Magnesium | 14 | $723 | $52 |
| Pantoprazole | 99 | $707 | $7 |
| Ondansetron Odt | 37 | $678 | $18 |
| Sucralfate | 19 | $627 | $33 |
| Ondansetron | 54 | $620 | $11 |
| Gabapentin | 52 | $533 | $10 |
| Bicalutamide | 26 | $524 | $20 |
| Diphenoxylate-Atropine | 29 | $511 | $18 |
| Morphine Sulfate Er | 15 | $508 | $34 |
| Prednisone | 62 | $499 | $8 |
| Levofloxacin | 45 | $421 | $9 |
| Potassium Chloride | 32 | $331 | $10 |
| Sertraline | 41 | $320 | $8 |
| Prochlorperazine Maleate | 53 | $307 | $6 |
| Sodium Chloride | 11 | $291 | $26 |
| Levetiracetam | 15 | $194 | $13 |
| Warfarin | 12 | $190 | $16 |
| Ibuprofen | 18 | $179 | $10 |
| Montelukast | 24 | $163 | $7 |
| Omeprazole | 27 | $156 | $6 |
| Alendronate | 31 | $147 | $5 |
| Alprazolam | 19 | $140 | $7 |
| Furosemide | 19 | $66 | $3 |
| Mirtazapine | 11 | $54 | $5 |
| Dexamethasone Sodium Phosphate | 11 | $29 | $3 |
| Atenolol | 12 | $20 | $2 |
| Diphenhydramine | 13 | $19 | $1 |
2016: 60 drugs
| Procrit | 284 | $986,998 | $3,475 |
| Revlimid | 59 | $665,282 | $11,276 |
| Ibrance | 36 | $378,733 | $10,520 |
| Avastin | 34 | $317,520 | $9,339 |
| Ninlaro | 27 | $240,746 | $8,917 |
| Herceptin | 44 | $211,133 | $4,798 |
| Opdivo | 18 | $193,605 | $10,756 |
| Erbitux | 16 | $141,911 | $8,869 |
| Tarceva | 17 | $118,582 | $6,975 |
| Zytiga | 16 | $112,247 | $7,015 |
| Xtandi | 11 | $99,606 | $9,055 |
| Neulasta | 18 | $93,244 | $5,180 |
| Alimta | 13 | $76,756 | $5,904 |
| Zarxio | 25 | $72,646 | $2,906 |
| Perjeta | 11 | $57,223 | $5,202 |
| Lupron Depot | 39 | $47,857 | $1,227 |
| Neupogen | 11 | $43,941 | $3,995 |
| Sandostatin Lar Depot | 11 | $38,442 | $3,495 |
| Sancuso | 34 | $35,843 | $1,054 |
| Xarelto | 49 | $22,401 | $457 |
| Exemestane | 57 | $15,654 | $275 |
| Prolia | 13 | $12,851 | $989 |
| Zoledronic Acid | 16 | $8,625 | $539 |
| Restasis | 19 | $8,169 | $430 |
| Pradaxa | 15 | $5,873 | $392 |
| Tamoxifen Citrate | 234 | $4,944 | $21 |
| Nexium | 15 | $3,666 | $244 |
| Crestor | 13 | $3,274 | $252 |
| Esomeprazole Magnesium | 25 | $2,730 | $109 |
| Hydrocodone-Acetaminophen | 62 | $2,149 | $35 |
| Pataday | 11 | $1,739 | $158 |
| Letrozole | 107 | $1,471 | $14 |
| Ibandronate | 27 | $1,428 | $53 |
| Anastrozole | 145 | $1,277 | $9 |
| Hydroxyurea | 45 | $835 | $19 |
| Dexamethasone | 52 | $710 | $14 |
| Methotrexate | 13 | $662 | $51 |
| Sodium Chloride | 20 | $629 | $31 |
| Bicalutamide | 24 | $600 | $25 |
| Gabapentin | 90 | $589 | $7 |
| Ondansetron Odt | 30 | $576 | $19 |
| Morphine Sulfate Er | 13 | $547 | $42 |
| Pantoprazole | 68 | $546 | $8 |
| Levofloxacin | 46 | $349 | $8 |
| Valsartan | 12 | $341 | $28 |
| Warfarin | 28 | $323 | $12 |
| Prochlorperazine Maleate | 44 | $302 | $7 |
| Ondansetron | 19 | $264 | $14 |
| Potassium Chloride | 21 | $232 | $11 |
| Diphenoxylate-Atropine | 11 | $222 | $20 |
| Ibuprofen | 22 | $179 | $8 |
| Prednisone | 25 | $176 | $7 |
| Levetiracetam | 16 | $160 | $10 |
| Sertraline | 19 | $110 | $6 |
| Alendronate | 15 | $86 | $6 |
| Montelukast | 11 | $76 | $7 |
| Amoxicillin | 13 | $60 | $5 |
| Alprazolam | 14 | $52 | $4 |
| Furosemide | 23 | $47 | $2 |
| Atenolol | 13 | $41 | $3 |
2015: 56 drugs
| Procrit | 293 | $936,363 | $3,196 |
| Revlimid | 43 | $443,746 | $10,320 |
| Rituxan | 19 | $317,614 | $16,717 |
| Avastin | 27 | $254,401 | $9,422 |
| Gleevec | 26 | $250,304 | $9,627 |
| Erbitux | 28 | $216,220 | $7,722 |
| Tarceva | 29 | $191,876 | $6,616 |
| Afinitor | 13 | $138,067 | $10,621 |
| Ibrance | 11 | $107,982 | $9,817 |
| Neulasta | 16 | $77,099 | $4,819 |
| Ixempra | 23 | $59,038 | $2,567 |
| Faslodex | 26 | $55,106 | $2,119 |
| Lupron Depot | 40 | $46,452 | $1,161 |
| Prolia | 16 | $14,715 | $920 |
| Xarelto | 34 | $11,001 | $324 |
| Exemestane | 42 | $10,942 | $261 |
| Nexium | 31 | $7,745 | $250 |
| Novolog Flexpen | 11 | $4,657 | $423 |
| Tamoxifen Citrate | 184 | $4,289 | $23 |
| Zoledronic Acid | 11 | $4,219 | $384 |
| Crestor | 13 | $2,793 | $215 |
| Novolog | 12 | $2,617 | $218 |
| Hydrocodone-Acetaminophen | 77 | $2,434 | $32 |
| Anastrozole | 116 | $2,061 | $18 |
| Ibandronate | 25 | $1,831 | $73 |
| Clindamycin Phosphate | 11 | $1,035 | $94 |
| Proair Hfa | 19 | $972 | $51 |
| Ondansetron | 45 | $909 | $20 |
| Hydroxyurea | 37 | $796 | $22 |
| Sucralfate | 35 | $785 | $22 |
| Pantoprazole | 76 | $627 | $8 |
| Bicalutamide | 30 | $540 | $18 |
| Sodium Chloride | 19 | $514 | $27 |
| Warfarin | 45 | $487 | $11 |
| Metoprolol | 13 | $484 | $37 |
| Letrozole | 49 | $426 | $9 |
| Diphenoxylate-Atropine | 17 | $405 | $24 |
| Levofloxacin | 54 | $369 | $7 |
| Tamsulosin | 14 | $354 | $25 |
| Prochlorperazine Maleate | 43 | $316 | $7 |
| Potassium Chloride | 22 | $289 | $13 |
| Gabapentin | 40 | $249 | $6 |
| Ondansetron Odt | 12 | $206 | $17 |
| Dexamethasone | 25 | $203 | $8 |
| Prednisone | 27 | $189 | $7 |
| Alendronate | 26 | $189 | $7 |
| Alcohol Prep Pads | 11 | $185 | $17 |
| Montelukast | 20 | $176 | $9 |
| Mirtazapine | 16 | $121 | $8 |
| Ibuprofen | 15 | $108 | $7 |
| Sertraline | 29 | $97 | $3 |
| Metoclopramide | 11 | $80 | $7 |
| Furosemide | 29 | $80 | $3 |
| Tramadol | 13 | $74 | $6 |
| Atenolol | 18 | $42 | $2 |
| Amlodipine Besylate | 13 | $40 | $3 |
2014: 65 drugs
| Procrit | 221 | $704,356 | $3,187 |
| Rituxan | 41 | $419,438 | $10,230 |
| Avastin | 52 | $339,570 | $6,530 |
| Tarceva | 49 | $299,888 | $6,120 |
| Xtandi | 16 | $132,582 | $8,286 |
| Treanda | 14 | $121,219 | $8,659 |
| Revlimid | 12 | $114,590 | $9,549 |
| Leukine | 23 | $102,812 | $4,470 |
| Faslodex | 31 | $65,410 | $2,110 |
| Neupogen | 13 | $45,001 | $3,462 |
| Sancuso | 15 | $18,963 | $1,264 |
| Lupron Depot | 16 | $16,861 | $1,054 |
| Xarelto | 39 | $11,357 | $291 |
| Pentasa | 12 | $10,074 | $839 |
| Gemcitabine | 28 | $8,350 | $298 |
| Diovan | 33 | $7,177 | $217 |
| Casodex | 12 | $6,445 | $537 |
| Exemestane | 24 | $5,794 | $241 |
| Carafate | 13 | $4,060 | $312 |
| Tradjenta | 12 | $3,562 | $297 |
| Anastrozole | 105 | $3,429 | $33 |
| Ibandronate | 43 | $3,426 | $80 |
| Crestor | 17 | $3,235 | $190 |
| Tamoxifen Citrate | 144 | $2,922 | $20 |
| Novolog | 16 | $2,874 | $180 |
| Paclitaxel | 11 | $2,508 | $228 |
| Carboplatin | 33 | $2,429 | $74 |
| Hydrocodone-Acetaminophen | 99 | $2,401 | $24 |
| Dexilant | 11 | $2,048 | $186 |
| Hydroxyurea | 42 | $1,156 | $28 |
| Letrozole | 45 | $1,041 | $23 |
| Anagrelide | 27 | $954 | $35 |
| Montelukast | 45 | $873 | $19 |
| Sucralfate | 34 | $741 | $22 |
| Bicalutamide | 36 | $715 | $20 |
| Lansoprazole | 20 | $683 | $34 |
| Pantoprazole | 71 | $666 | $9 |
| Tamsulosin | 39 | $573 | $15 |
| Temazepam | 22 | $500 | $23 |
| Ondansetron | 27 | $488 | $18 |
| Warfarin | 43 | $451 | $10 |
| Sodium Chloride | 11 | $387 | $35 |
| Prednisone | 51 | $376 | $7 |
| Levofloxacin | 40 | $282 | $7 |
| Venlafaxine Hcl Er | 20 | $271 | $14 |
| Gabapentin | 20 | $223 | $11 |
| Sertraline | 42 | $200 | $5 |
| Triamcinolone Acetonide | 14 | $188 | $13 |
| Prochlorperazine Maleate | 24 | $188 | $8 |
| Dexamethasone | 19 | $151 | $8 |
| Atenolol | 22 | $148 | $7 |
| Sure Comfort | 12 | $146 | $12 |
| Tramadol | 20 | $128 | $6 |
| Alprazolam | 19 | $126 | $7 |
| Ibuprofen | 17 | $112 | $7 |
| Allopurinol | 15 | $106 | $7 |
| Alendronate | 15 | $101 | $7 |
| Lorazepam | 17 | $97 | $6 |
| Metoclopramide | 12 | $90 | $8 |
| Cephalexin | 11 | $88 | $8 |
| Mirtazapine | 11 | $85 | $8 |
| Ranitidine | 14 | $72 | $5 |
| Furosemide | 22 | $69 | $3 |
| Amlodipine Besylate | 18 | $59 | $3 |
| Glipizide | 12 | $36 | $3 |
2013: 58 drugs
| Rituxan | None | 58 | $663,307 | $11,436 |
| Procrit | None | 176 | $515,132 | $2,927 |
| Avastin | None | 68 | $498,212 | $7,327 |
| Leukine | None | 69 | $285,094 | $4,132 |
| Tarceva | None | 50 | $278,782 | $5,576 |
| Treanda | None | 24 | $142,972 | $5,957 |
| Herceptin | None | 16 | $100,821 | $6,301 |
| Sancuso | None | 85 | $90,476 | $1,064 |
| Zytiga | None | 12 | $75,464 | $6,289 |
| Faslodex | None | 24 | $53,602 | $2,233 |
| Gammagard Liquid | Immune globulin | 16 | $52,125 | $3,258 |
| Lupron Depot | None | 34 | $33,335 | $980 |
| Fondaparinux | None | 14 | $22,551 | $1,611 |
| Xarelto | None | 36 | $9,622 | $267 |
| Pentasa | None | 11 | $8,518 | $774 |
| Carafate | None | 21 | $5,438 | $259 |
| Anagrelide | None | 25 | $5,108 | $204 |
| Ibandronate | None | 49 | $5,020 | $102 |
| Nexium | None | 20 | $4,270 | $213 |
| Exemestane | None | 17 | $4,181 | $246 |
| Diovan | None | 20 | $4,070 | $203 |
| Crestor | None | 23 | $3,974 | $173 |
| Anastrozole | None | 46 | $2,522 | $55 |
| Ondansetron | None | 77 | $2,217 | $29 |
| Tamoxifen Citrate | None | 142 | $2,185 | $15 |
| Letrozole | None | 68 | $2,099 | $31 |
| Novolog | None | 13 | $2,004 | $154 |
| Hydrocodone-Acetaminophen | None | 98 | $1,553 | $16 |
| Hydroxyurea | None | 55 | $1,379 | $25 |
| Pantoprazole | None | 100 | $1,201 | $12 |
| Levofloxacin | None | 71 | $695 | $10 |
| Sucralfate | None | 25 | $634 | $25 |
| Venlafaxine Hcl Er | None | 21 | $485 | $23 |
| Triamcinolone Acetonide | None | 28 | $473 | $17 |
| Tamsulosin | None | 36 | $468 | $13 |
| Bicalutamide | None | 13 | $446 | $34 |
| Dexamethasone | None | 24 | $306 | $13 |
| Lorazepam | None | 34 | $269 | $8 |
| Warfarin | None | 27 | $260 | $10 |
| Potassium Chloride | None | 16 | $252 | $16 |
| Metoclopramide | None | 22 | $252 | $11 |
| Tramadol | None | 33 | $251 | $8 |
| Gabapentin | None | 20 | $248 | $12 |
| Prochlorperazine Maleate | None | 32 | $246 | $8 |
| Prednisone | None | 51 | $205 | $4 |
| Venlafaxine | None | 11 | $205 | $19 |
| Ibuprofen | None | 23 | $155 | $7 |
| Levothyroxine | None | 15 | $152 | $10 |
| Sertraline | None | 24 | $148 | $6 |
| Furosemide | None | 38 | $148 | $4 |
| Diphenoxylate-Atropine | None | 18 | $135 | $7 |
| Omeprazole | None | 12 | $115 | $10 |
| Zolpidem | None | 25 | $106 | $4 |
| Atenolol | None | 15 | $105 | $7 |
| Azithromycin | None | 11 | $103 | $9 |
| Alendronate | None | 11 | $99 | $9 |
| Alprazolam | None | 15 | $68 | $5 |
| Lisinopril | None | 11 | $55 | $5 |
Money from drug and device companies
$7,192 in 2025
| 2025 | 52 | 244 | None | $7,192 |
| 2024 | 48 | 252 | None | $6,506 |
| 2023 | 47 | 209 | None | $5,466 |
| 2022 | 44 | 212 | None | $4,723 |
| 2021 | 45 | 176 | None | $3,825 |
| 2020 | 51 | 186 | $1,000 | $4,903 |
| 2019 | 38 | 261 | None | $5,154 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Novartis Pharmaceuticals | Kisqali | $1,012 | 22 payments
|
| Janssen Biotech | Erleada | $668 | 21 payments
|
| AstraZeneca Pharmaceuticals LP | Enhertu | $581 | 21 payments
|
| Merck Sharp & Dohme | Keytruda | $359 | 12 payments
|
| Pfizer | Tivdak | $305 | 14 payments
|
| Astellas Pharma US | Vyloy | $237 | 8 payments
|
See all 240 published payments
| Daiichi Sankyo | Meals · 2025-12-30 | Enhertu | $28 |
| Legend Biotech USA | Education · 2025-12-19 | Carvykti | $16 |
| Legend Biotech USA | Meals · 2025-12-19 | Carvykti | $30 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-12-18 | Calquence | $24 |
| Janssen Biotech | Meals · 2025-12-17 | Erleada | $37 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-12-16 | Fruzaqla | $45 |
| Novartis Pharmaceuticals | Meals · 2025-12-10 | Scemblix | $17 |
| Astellas Pharma US | Meals · 2025-12-09 | Padcev | $32 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-12-08 | Tagrisso | $33 |
| Amgen | Meals · 2025-12-04 | None | $122 |
| Janssen Biotech | Meals · 2025-12-03 | Tecvayli | $14 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-12-03 | None | $15 |
| Deciphera Pharmaceuticals | Meals · 2025-12-01 | Qinlock | $22 |
| Incyte | Meals · 2025-11-27 | Monjuvi | $6 |
| Incyte | Meals · 2025-11-26 | Monjuvi | $23 |
| Genzyme | Meals · 2025-11-26 | Wayrilz | $29 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-11-25 | Nubeqa | $20 |
| EMD Serono | Meals · 2025-11-24 | None | $28 |
| Pfizer | Meals · 2025-11-21 | Tivdak | $37 |
| Geron | Meals · 2025-11-20 | Rytelo | $28 |
| Celgene | Meals · 2025-11-19 | Reblozyl | $27 |
| Gilead Sciences | Meals · 2025-11-17 | Trodelvy | $30 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-11-14 | None | $19 |
| Caris MPI | Meals · 2025-11-14 | Mi Cancer Seek | $33 |
| AstraZeneca Pharmaceuticals LP | Education · 2025-11-13 | Imfinzi | $35 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-11-13 | Enhertu | $24 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-11-12 | Opdivo | $11 |
| Eisai | Meals · 2025-11-11 | Lenvima | $19 |
| Merck Sharp & Dohme | Meals · 2025-11-05 | Keytruda Qlex | $34 |
| TerSera Therapeutics | Meals · 2025-11-04 | Xermelo | $34 |
| Novartis Pharmaceuticals | Meals · 2025-11-03 | Kisqali | $27 |
| Kite Pharma | Meals · 2025-11-03 | Yescarta | $24 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-10-30 | Opdualag | $20 |
| Coherus Oncology | Meals · 2025-10-28 | Loqtorzi | $22 |
| Incyte | Meals · 2025-10-27 | Jakafi | $28 |
| Janssen Biotech | Meals · 2025-10-24 | Carvykti | $26 |
| Janssen Biotech | Meals · 2025-10-23 | Tecvayli | $29 |
| Exelixis | Meals · 2025-10-23 | Cabometyx | $32 |
| Genzyme | Meals · 2025-10-21 | Wayrilz | $31 |
| Array Biopharma | Meals · 2025-10-20 | Braftovi | $24 |
| BeOne Medicines USA | Meals · 2025-10-17 | Tevimbra | $29 |
| Caris MPI | Meals · 2025-10-16 | Mi Cancer Seek | $23 |
| Merck Sharp & Dohme | Meals · 2025-10-15 | Keytruda | $29 |
| Incyte | Meals · 2025-10-14 | Monjuvi | $30 |
| Janssen Biotech | Meals · 2025-10-13 | Rybrevant | $29 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-10-10 | Lynparza | $18 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-10-10 | Imfinzi | $27 |
| Celgene | Meals · 2025-10-09 | Reblozyl | $31 |
| Stemline Therapeutics | Meals · 2025-10-08 | Orserdu | $31 |
| Amgen | Meals · 2025-10-07 | Lumakras | $23 |
| Amgen | Meals · 2025-10-07 | Imdelltra (Amg757) | $23 |
| Merck Sharp & Dohme | Meals · 2025-10-06 | Keytruda Qlex | $30 |
| Janssen Biotech | Meals · 2025-10-03 | Erleada | $34 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-10-01 | Iclusig | $39 |
| GlaxoSmithKline | Meals · 2025-09-30 | Ojjaara | $25 |
| AstraZeneca Pharmaceuticals LP | Education · 2025-09-30 | None | $88 |
| Novartis Pharmaceuticals | Meals · 2025-09-29 | Scemblix | $1 |
| Novartis Pharmaceuticals | Meals · 2025-09-29 | Scemblix | $3 |
| Novartis Pharmaceuticals | Meals · 2025-09-29 | Scemblix | $24 |
| Jazz Pharmaceuticals | Meals · 2025-09-26 | Zepzelca | $30 |
| Astellas Pharma US | Meals · 2025-09-25 | Xtandi | $19 |
| Genentech USA | Meals · 2025-09-24 | Venclexta | $32 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-09-23 | Tagrisso | $32 |
| Abbvie | Meals · 2025-09-22 | Elahere | $26 |
| Regeneron Healthcare Solutions | Meals · 2025-09-19 | Lynozyfic | $38 |
| Seagen | Education · 2025-09-18 | None | $100 |
| Progenics Pharmaceuticals | Meals · 2025-09-18 | Pylarify | $27 |
| Karyopharm Therapeutics | Meals · 2025-09-17 | Xpovio | $29 |
| Adc Therapeutics America | Meals · 2025-09-16 | Zynlonta | $26 |
| Geron | Meals · 2025-09-15 | Rytelo | $29 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-09-12 | None | $29 |
| Array Biopharma | Meals · 2025-09-11 | Lorbrena | $33 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-09-10 | Calquence | $30 |
| Celgene | Meals · 2025-09-09 | Reblozyl | $28 |
| Celgene | Meals · 2025-09-09 | Reblozyl | $1 |
| Karyopharm Therapeutics | Meals · 2025-09-08 | Xpovio | $27 |
| AstraZeneca Pharmaceuticals LP | Education · 2025-09-05 | Enhertu | $26 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-09-05 | Enhertu | $26 |
| Genentech USA | Meals · 2025-09-04 | Phesgo | $10 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-09-03 | Nubeqa | $27 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-09-02 | None | $20 |
| Pfizer | Meals · 2025-08-29 | Tivdak | $40 |
| Ipsen Biopharmaceuticals | Meals · 2025-08-27 | Somatuline Depot | $23 |
| Pfizer | Meals · 2025-08-27 | Tivdak | $6 |
| Janssen Biotech | Meals · 2025-08-26 | Erleada | $45 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-08-25 | Opdualag | $22 |
| Servier Pharmaceuticals | Meals · 2025-08-22 | Tibsovo | $25 |
| Novartis Pharmaceuticals | Long term medical supply or device loan · 2025-08-21 | Kisqali | $83 |
| Exelixis | Meals · 2025-08-21 | Cabometyx | $24 |
| PharmaEssentia USA | Meals · 2025-08-20 | Besremi | $20 |
| Novartis Pharmaceuticals | Meals · 2025-08-19 | Kisqali | $25 |
| Pfizer | Meals · 2025-08-18 | Tivdak | $2 |
| Merck Sharp & Dohme | Meals · 2025-08-18 | Keytruda | $32 |
| Janssen Biotech | Meals · 2025-08-15 | Carvykti | $28 |
| Caris MPI | Meals · 2025-08-14 | Mi Cancer Seek | $29 |
| Syndax Pharmaceuticals | Meals · 2025-08-14 | None | $29 |
| Genzyme | Meals · 2025-08-13 | Ayvakit | $26 |
| Agios Pharmaceuticals | Meals · 2025-08-12 | Pyrukynd | $31 |
| Caris MPI | Meals · 2025-08-08 | Mi Cancer Seek | $131 |
| Janssen Biotech | Meals · 2025-08-07 | Tecvayli | $21 |
| Sobi | Meals · 2025-08-06 | Vonjo | $27 |
| Incyte | Meals · 2025-08-05 | Jakafi | $30 |
| Merck Sharp & Dohme | Meals · 2025-08-04 | Keytruda | $25 |
| Karyopharm Therapeutics | Meals · 2025-08-01 | Xpovio | $21 |
| Seagen | Education · 2025-07-31 | None | $79 |
| Incyte | Meals · 2025-07-30 | Jakafi | $30 |
| Pfizer | Meals · 2025-07-29 | Ibrance | $23 |
| Stemline Therapeutics | Meals · 2025-07-28 | Orserdu | $35 |
| Novartis Pharmaceuticals | Long term medical supply or device loan · 2025-07-25 | Kisqali | $100 |
| Kite Pharma | Meals · 2025-07-25 | Yescarta | $26 |
| Astellas Pharma US | Education · 2025-07-24 | None | $100 |
| TerSera Therapeutics | Meals · 2025-07-24 | Zoladex | $27 |
| Array Biopharma | Meals · 2025-07-23 | Braftovi | $26 |
| Eisai | Meals · 2025-07-22 | Lenvima | $24 |
| Janssen Biotech | Meals · 2025-07-18 | Rybrevant | $29 |
| Taiho Oncology | Meals · 2025-07-17 | Lonsurf | $24 |
| Merck Sharp & Dohme | Meals · 2025-07-17 | Welireg | $33 |
| Merck Sharp & Dohme | Meals · 2025-07-16 | Keytruda | $27 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-07-15 | Nubeqa | $27 |
| Gilead Sciences | Meals · 2025-07-10 | Trodelvy | $31 |
| Genmab U.S. | Meals · 2025-07-09 | Epkinly | $34 |
| Janssen Biotech | Education · 2025-06-27 | Erleada | $100 |
| Celgene | Meals · 2025-06-27 | Reblozyl | $30 |
| Janssen Biotech | Meals · 2025-06-19 | Darzalex | $32 |
| Exelixis | Meals · 2025-06-18 | Cabometyx | $26 |
| Geron | Meals · 2025-06-17 | Rytelo | $24 |
| Janssen Biotech | Meals · 2025-06-13 | Tecvayli | $21 |
| BeOne Medicines USA | Meals · 2025-06-13 | Brukinsa | $24 |
| Novartis Pharmaceuticals | Long term medical supply or device loan · 2025-06-12 | Kisqali | $100 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-06-12 | None | $30 |
| Blueprint Medicines | Meals · 2025-06-11 | Ayvakit | $41 |
| Legend Biotech USA | Meals · 2025-06-10 | Carvykti | $26 |
| Pfizer | Meals · 2025-06-06 | Tivdak | $36 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-06-05 | Opdualag | $19 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-06-03 | None | $16 |
| Janssen Biotech | Meals · 2025-05-30 | Erleada | $29 |
| Pfizer | Meals · 2025-05-28 | Elrexfio | $23 |
| Incyte | Meals · 2025-05-27 | Jakafi | $28 |
| Abbvie | Meals · 2025-05-23 | Elahere | $29 |
| Novartis Pharmaceuticals | Meals · 2025-05-21 | Scemblix | $25 |
| Novartis Pharmaceuticals | Meals · 2025-05-21 | Scemblix | $3 |
| Genentech USA | Meals · 2025-05-20 | Phesgo | $28 |
| Alexion Pharmaceuticals | Meals · 2025-05-18 | Ultomiris | $28 |
| Array Biopharma | Meals · 2025-05-16 | Braftovi | $26 |
| Caris MPI | Meals · 2025-05-16 | Mi Cancer Seek | $5 |
| Caris MPI | Meals · 2025-05-16 | Mi Cancer Seek | $5 |
| Novartis Pharmaceuticals | Long term medical supply or device loan · 2025-05-15 | Kisqali | $100 |
| Eisai | Meals · 2025-05-15 | Lenvima | $27 |
| Janssen Biotech | Meals · 2025-05-13 | Carvykti | $30 |
| Kite Pharma | Meals · 2025-05-13 | Yescarta | $29 |
| Deciphera Pharmaceuticals | Meals · 2025-05-12 | Qinlock | $26 |
| Syndax Pharmaceuticals | Meals · 2025-05-08 | None | $20 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-05-07 | None | $20 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-05-05 | Tagrisso | $31 |
| Janssen Biotech | Meals · 2025-05-02 | Erleada | $29 |
| Novartis Pharmaceuticals | Meals · 2025-05-01 | Kisqali | $21 |
| Abbvie | Meals · 2025-04-30 | Elahere | $25 |
| Astellas Pharma US | Meals · 2025-04-28 | Vyloy | $31 |
| Astellas Pharma US | Meals · 2025-04-28 | Vyloy | $2 |
| Novartis Pharmaceuticals | Long term medical supply or device loan · 2025-04-24 | Kisqali | $100 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-04-23 | Opdivo | $17 |
| Pfizer | Meals · 2025-04-21 | Elrexfio | $19 |
| Tempus AI | Meals · 2025-04-21 | Xt Cdx | $26 |
| Merck Sharp & Dohme | Meals · 2025-04-18 | Welireg | $31 |
| Genentech USA | Meals · 2025-04-17 | Venclexta | $24 |
| Exelixis | Meals · 2025-04-16 | Cabometyx | $36 |
| Novartis Pharmaceuticals | Meals · 2025-04-15 | Kisqali | $22 |
| Astellas Pharma US | Meals · 2025-04-14 | Xtandi | $30 |
| Merck Sharp & Dohme | Meals · 2025-04-11 | Lynparza | $32 |
| Taiho Oncology | Meals · 2025-04-10 | Lonsurf | $24 |
| Janssen Biotech | Meals · 2025-04-09 | Erleada | $28 |
| Janssen Biotech | Meals · 2025-04-08 | Tecvayli | $24 |
| Blueprint Medicines | Meals · 2025-04-07 | Ayvakit | $45 |
| BeOne Medicines USA | Meals · 2025-04-04 | Tevimbra | $32 |
| Agios Pharmaceuticals | Meals · 2025-04-02 | Pyrukynd | $29 |
| Sobi | Meals · 2025-04-01 | Vonjo | $25 |
| Gilead Sciences | Meals · 2025-03-31 | Trodelvy | $20 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-03-28 | None | $29 |
| PharmaEssentia USA | Meals · 2025-03-27 | Besremi | $27 |
| Novartis Pharmaceuticals | Long term medical supply or device loan · 2025-03-26 | Kisqali | $100 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-03-26 | Nubeqa | $26 |
| Incyte | Meals · 2025-03-24 | Jakafi | $28 |
| Daiichi Sankyo | Meals · 2025-03-21 | Enhertu | $29 |
| Pfizer | Meals · 2025-03-21 | Ibrance | $24 |
| Novartis Pharmaceuticals | Meals · 2025-03-20 | Scemblix | $14 |
| Novartis Pharmaceuticals | Meals · 2025-03-20 | Scemblix | $6 |
| Kite Pharma | Meals · 2025-03-19 | Yescarta | $24 |
| TerSera Therapeutics | Meals · 2025-03-18 | Zoladex | $38 |
| Adc Therapeutics America | Meals · 2025-03-17 | Zynlonta | $24 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-03-13 | Calquence | $31 |
| Geron | Meals · 2025-03-12 | Rytelo | $34 |
| Azurity Pharmaceuticals | Meals · 2025-03-11 | Danziten | $18 |
| GlaxoSmithKline | Meals · 2025-03-10 | Ojjaara | $16 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-03-07 | Enhertu | $24 |
| EMD Serono | Meals · 2025-03-06 | None | $24 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-03-05 | Iclusig | $39 |
| Abbvie | Meals · 2025-03-04 | Elahere | $22 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-03-03 | None | $21 |
| Pfizer | Meals · 2025-02-28 | Tivdak | $32 |
| Celgene | Meals · 2025-02-26 | Reblozyl | $32 |
| Pfizer | Meals · 2025-02-26 | Tivdak | $9 |
| Acrotech Biopharma | Meals · 2025-02-26 | Beleodaq | $31 |
| Gilead Sciences | Meals · 2025-02-25 | Trodelvy | $29 |
| Astellas Pharma US | Meals · 2025-02-24 | Vyloy | $21 |
| Astellas Pharma US | Meals · 2025-02-23 | Vyloy | $2 |
| Novartis Pharmaceuticals | Long term medical supply or device loan · 2025-02-21 | Kisqali | $100 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-02-19 | Vonvendi | $21 |
| Incyte | Meals · 2025-02-19 | Jakafi | $29 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-02-18 | Tagrisso | $31 |
| Daiichi Sankyo | Meals · 2025-02-17 | Enhertu | $25 |
| Pfizer | Meals · 2025-02-14 | Bosulif | $21 |
| Novartis Pharmaceuticals | Meals · 2025-02-13 | Kisqali | $22 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-02-12 | Opdualag | $24 |
| GlaxoSmithKline | Meals · 2025-02-11 | Ojjaara | $23 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-02-10 | Imfinzi | $21 |
| Celgene | Meals · 2025-02-07 | Opdivo | $26 |
| Merck Sharp & Dohme | Meals · 2025-02-06 | Keytruda | $34 |
| Abbvie | Meals · 2025-02-05 | Venclexta | $16 |
| Janssen Biotech | Meals · 2025-02-03 | Rybrevant | $34 |
| Pfizer | Meals · 2025-02-03 | Xtandi | $16 |
| Genmab U.S. | Meals · 2025-02-03 | Epkinly | $34 |
| Merck Sharp & Dohme | Meals · 2025-01-31 | Keytruda | $26 |
| Daiichi Sankyo | Meals · 2025-01-30 | Enhertu | $28 |
| Pfizer | Meals · 2025-01-29 | Xtandi | $16 |
| Janssen Biotech | Meals · 2025-01-28 | Tecvayli | $24 |
| Array Biopharma | Meals · 2025-01-27 | Xalkori | $24 |
| Janssen Biotech | Meals · 2025-01-24 | Carvykti | $25 |
| Novartis Pharmaceuticals | Long term medical supply or device loan · 2025-01-23 | Kisqali | $100 |
| Merck Sharp & Dohme | Meals · 2025-01-23 | Keytruda | $27 |
| Genmab U.S. | Meals · 2025-01-22 | Epkinly | $33 |
| Genentech USA | Meals · 2025-01-21 | Venclexta | $30 |
| Novartis Pharmaceuticals | Meals · 2025-01-20 | Kisqali | $21 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-01-17 | Opdivo | $10 |
| PharmaEssentia USA | Meals · 2025-01-16 | Besremi | $30 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-01-15 | Lynparza | $14 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-01-15 | Lynparza | $19 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-01-14 | Enhertu | $24 |
| AstraZeneca Pharmaceuticals LP | Education · 2025-01-14 | Enhertu | $7 |
| Lilly USA | Meals · 2025-01-13 | Verzenio | $30 |
| Genentech USA | Meals · 2025-01-10 | Polivy | $31 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $6,506
| Novartis Pharmaceuticals | Kisqali | $716 | 18 payments
|
| AstraZeneca Pharmaceuticals LP | Tagrisso | $542 | 19 payments
|
| Celgene | Reblozyl | $382 | 23 payments
|
| Janssen Biotech | Rybrevant | $340 | 10 payments
|
| Pfizer | Ibrance | $314 | 18 payments
|
| Incyte | Jakafi | $305 | 9 payments
|
| Abbvie | Imbruvica | $277 | 10 payments
|
| Eisai | Lenvima | $271 | 11 payments
|
| Lilly USA | Verzenio | $252 | 9 payments
|
| Merck Sharp & Dohme | Keytruda | $206 | 7 payments
|
| E.R. Squibb & Sons L.L.C. | Opdivo | $204 | 11 payments
|
| Takeda Pharmaceuticals U.S.A. | Fruzaqla | $198 | 7 payments
|
| Astellas Pharma US | Xospata | $178 | 12 payments
|
| Gilead Sciences | None | $167 | 6 payments
|
| Genentech USA | Itovebi | $141 | 6 payments
|
| TerSera Therapeutics | Zoladex | $132 | 4 payments
|
| Boehringer Ingelheim Pharmaceuticals | Gilotrif | $121 | 4 payments
|
| Regeneron Healthcare Solutions | Libtayo | $111 | 3 payments
|
| Immunocore | Kimmtrak | $107 | 3 payments
|
| Blueprint Medicines | Ayvakit | $102 | 3 payments
|
| PharmaEssentia USA | Besremi | $100 | 4 payments
|
| ADC Therapeutics America | None | $97 | 3 payments
|
| Bayer Healthcare Pharmaceuticals | Nubeqa | $93 | 4 payments
|
| Exelixis | Cabometyx | $92 | 3 payments
|
| Alexion Pharmaceuticals | Ultomiris | $90 | 3 payments
|
| Genzyme | Sarclisa | $88 | 3 payments
|
| EMD Serono | None | $86 | 3 payments
|
| Sun Pharmaceutical Industries | Yonsa | $79 | 3 payments
|
| Sobi | Doptelet | $76 | 2 payments
|
| Array Biopharma | Xalkori | $75 | 3 payments
|
| Genmab U.S. | Epkinly | $64 | 2 payments
|
| Kite Pharma | Yescarta | $49 | 2 payments
|
| Jazz Pharmaceuticals | Zepzelca | $44 | 2 payments
|
| GlaxoSmithKline | Ojjaara | $44 | 2 payments
|
| Karyopharm Therapeutics | Xpovio | $43 | 2 payments
|
| Apellis Pharmaceuticals | Empaveli | $32 | 1 payment
|
| SpringWorks Therapeutics | Ogsiveo | $30 | 1 payment
|
| Pharmacosmos Therapeutics | Monoferric | $29 | 1 payment
|
| Tempus AI | Xt Cdx | $28 | 2 payments
|
| Puma Biotechnology | None | $27 | 1 payment
|
| Ipsen Biopharmaceuticals | Onivyde | $27 | 1 payment
|
| Daiichi Sankyo | Enhertu | $26 | 1 payment
|
| Taiho Oncology | Lonsurf | $25 | 1 payment
|
| Mirati Therapeutics | Krazati | $20 | 1 payment
|
| Deciphera Pharmaceuticals | Qinlock | $20 | 1 payment
|
| Fennec Pharmaceuticals | Pedmark | $19 | 1 payment
|
| Chiesi USA | Ferriprox | $19 | 1 payment
|
| BeiGene USA | Brukinsa | $18 | 1 payment
|
2023: $5,466
| Novartis Pharmaceuticals | Tabrecta | $399 | 14 payments
|
| Incyte | Jakafi | $383 | 13 payments
|
| AstraZeneca Pharmaceuticals LP | Enhertu | $329 | 8 payments
|
| Pfizer | Xtandi | $308 | 15 payments
|
| Genzyme | Sarclisa | $270 | 10 payments
|
| Seagen | Adcetris | $262 | 11 payments
|
| Celgene | Reblozyl | $251 | 9 payments
|
| Merck Sharp & Dohme | Keytruda | $211 | 8 payments
|
| Genentech USA | Venclexta | $188 | 11 payments
|
| Astellas Pharma US | Xospata | $187 | 8 payments
|
| E.R. Squibb & Sons L.L.C. | Opdivo | $169 | 8 payments
|
| Bayer Healthcare Pharmaceuticals | Stivarga | $160 | 6 payments
|
| Regeneron Healthcare Solutions | Libtayo | $154 | 5 payments
|
| Janssen Scientific Affairs | Erleada | $145 | 1 payment
|
| Blueprint Medicines | Ayvakit | $144 | 4 payments
|
| Janssen Biotech | Rybrevant | $124 | 6 payments
|
| TerSera Therapeutics | Zoladex | $123 | 4 payments
|
| Takeda Pharmaceuticals U.S.A. | Iclusig | $115 | 4 payments
|
| Mirati Therapeutics | Krazati | $109 | 5 payments
|
| Eisai | Lenvima | $99 | 4 payments
|
| Karyopharm Therapeutics | Xpovio | $98 | 3 payments
|
| Puma Biotechnology | Nerlynx | $97 | 4 payments
|
| Amgen | Lumakras | $88 | 3 payments
|
| BeiGene USA | Brukinsa | $86 | 4 payments
|
| Gilead Sciences | Trodelvy | $82 | 3 payments
|
| Array Biopharma | Xalkori | $80 | 4 payments
|
| Lilly USA | Verzenio | $78 | 3 payments
|
| GlaxoSmithKline | Zejula | $74 | 3 payments
|
| Stemline Therapeutics | Orserdu | $70 | 3 payments
|
| ImmunoGen | Elahere | $67 | 3 payments
|
| Exelixis | Cabometyx | $50 | 2 payments
|
| Taiho Oncology | Lonsurf | $48 | 2 payments
|
| Deciphera Pharmaceuticals | Qinlock | $48 | 2 payments
|
| MorphoSys US | Monjuvi | $42 | 2 payments
|
| Daiichi Sankyo | Enhertu | $41 | 2 payments
|
| Sobi | Doptelet | $37 | 1 payment
|
| Boehringer Ingelheim Pharmaceuticals | Gilotrif | $31 | 1 payment
|
| Octapharma USA | Panzyga | $30 | 1 payment
|
| Alexion Pharmaceuticals | Ultomiris | $28 | 1 payment
|
| PharmaEssentia USA | Besremi | $25 | 1 payment
|
| EMD Serono | Bavencio | $24 | 1 payment
|
| Foundation Medicine | None | $21 | 1 payment
|
| Rigel Pharmaceuticals | Rezlidhia | $21 | 1 payment
|
| AVEO Pharmaceuticals | Fotivda | $20 | 1 payment
|
| Verity Pharmaceuticals | Trelstar | $20 | 1 payment
|
| Organon | Ontruzant | $18 | 1 payment
|
| Spectrum Pharmaceuticals | Rolvedon | $14 | 1 payment
|
2022: $4,723
| Novartis Pharmaceuticals | Kisqali | $512 | 12 payments
|
| Incyte | Jakafi | $316 | 11 payments
|
| Celgene | Reblozyl | $284 | 12 payments
|
| Janssen Biotech | Darzalex | $275 | 10 payments
|
| Pfizer | Xtandi | $255 | 13 payments
|
| E.R. Squibb & Sons L.L.C. | Opdivo | $238 | 15 payments
|
| Exelixis | Cabometyx | $220 | 3 payments
|
| AstraZeneca Pharmaceuticals LP | Lynparza | $181 | 8 payments
|
| Bayer HealthCare Pharmaceuticals | Nubeqa | $176 | 7 payments
|
| Seagen | Adcetris | $153 | 7 payments
|
| Amgen | Lumakras | $147 | 6 payments
|
| Eisai | Lenvima | $145 | 7 payments
|
| Takeda Pharmaceuticals U.S.A. | Iclusig | $143 | 5 payments
|
| Genzyme | Sarclisa | $120 | 5 payments
|
| Lilly USA | Verzenio | $110 | 4 payments
|
| Karyopharm Therapeutics | Xpovio | $101 | 3 payments
|
| Gilead Sciences | Trodelvy | $90 | 4 payments
|
| Astellas Pharma US | Xtandi | $88 | 4 payments
|
| TerSera Therapeutics | Xermelo | $86 | 3 payments
|
| Blueprint Medicines | Ayvakit | $84 | 3 payments
|
| Genentech USA | Venclexta | $82 | 7 payments
|
| Daiichi Sankyo | Enhertu | $81 | 3 payments
|
| Pharmacyclics LLC an AbbVie | Imbruvica | $80 | 3 payments
|
| Merck Sharp & Dohme | Keytruda | $78 | 4 payments
|
| Array Biopharma | Braftovi | $73 | 3 payments
|
| PharmaEssentia USA | Besremi | $61 | 3 payments
|
| Sun Pharmaceutical Industries | Yonsa | $59 | 2 payments
|
| Puma Biotechnology | Nerlynx | $56 | 3 payments
|
| Kite Pharma | None | $49 | 2 payments
|
| Kyowa Kirin | Poteligeo | $40 | 2 payments
|
| GE HealthCare | None | $39 | 1 payment
|
| TOLMAR Pharmaceuticals | Eligard | $36 | 2 payments
|
| Regeneron Healthcare Solutions | Libtayo | $34 | 1 payment
|
| Organon | None | $26 | 1 payment
|
| Clovis Oncology | Rubraca | $24 | 1 payment
|
| BeiGene USA | Brukinsa | $23 | 1 payment
|
| EMD Serono | None | $23 | 1 payment
|
| Alexion Pharmaceuticals | Ultomiris | $22 | 1 payment
|
| Sobi | Gamifant | $22 | 1 payment
|
| Boehringer Ingelheim Pharmaceuticals | Gilotrif | $19 | 1 payment
|
| MorphoSys US | Monjuvi | $19 | 1 payment
|
| GlaxoSmithKline | Zejula | $18 | 1 payment
|
| Chiesi USA | Ferriprox | $16 | 1 payment
|
| Abbvie | Venclexta | $16 | 1 payment
|
2021: $3,825
| Genzyme | Sarclisa | $275 | 14 payments
|
| Karyopharm Therapeutics | Xpovio | $212 | 7 payments
|
| Merck Sharp & Dohme | Keytruda | $202 | 10 payments
|
| AstraZeneca Pharmaceuticals LP | Lynparza | $200 | 11 payments
|
| Novartis Pharmaceuticals | Kisqali | $199 | 2 payments
|
| Seagen | Adcetris | $198 | 9 payments
|
| Amgen | Nplate | $196 | 9 payments
|
| Incyte | Monjuvi | $169 | 8 payments
|
| Celgene | Onureg | $167 | 8 payments
|
| Pfizer | Ibrance | $157 | 12 payments
|
| Blueprint Medicines | Gavreto | $132 | 4 payments
|
| Bayer HealthCare Pharmaceuticals | Stivarga | $129 | 6 payments
|
| Exelixis | Cabometyx | $124 | 5 payments
|
| Dova Pharmaceuticals | Doptelet | $111 | 5 payments
|
| Eisai | Lenvima | $102 | 5 payments
|
| Takeda Pharmaceuticals U.S.A. | Ninlaro | $89 | 4 payments
|
| Kite Pharma | None | $85 | 3 payments
|
| Lilly USA | Verzenio | $79 | 4 payments
|
| Janssen Biotech | Erleada | $78 | 4 payments
|
| Pharmacyclics LLC An AbbVie | Imbruvica | $77 | 3 payments
|
| E.R. Squibb & Sons L.L.C. | Opdivo | $75 | 4 payments
|
| Puma Biotechnology | Nerlynx | $69 | 4 payments
|
| Coherus Biosciences | Udenyca | $66 | 2 payments
|
| TOLMAR Pharmaceuticals | Eligard | $65 | 4 payments
|
| Astellas Pharma US | Xospata | $53 | 3 payments
|
| Alexion Pharmaceuticals | Ultomiris | $47 | 2 payments
|
| Daiichi Sankyo | Injectafer | $45 | 2 payments
|
| Boehringer Ingelheim Pharmaceuticals | Gilotrif | $39 | 2 payments
|
| AMAG Pharmaceuticals | Feraheme | $38 | 2 payments
|
| Genentech USA | Phesgo | $38 | 2 payments
|
| Rigel Pharmaceuticals | Tavalisse | $30 | 2 payments
|
| Emmaus Medical | Endari | $25 | 1 payment
|
| Myriad Genetic Laboratories | Myrisk | $25 | 1 payment
|
| Taiho Oncology | Inqovi | $24 | 1 payment
|
| AbbVie | Venclexta | $24 | 1 payment
|
| TerSera Therapeutics | Xermelo | $24 | 1 payment
|
| BeiGene USA | Brukinsa | $22 | 1 payment
|
| EMD Serono | None | $21 | 1 payment
|
| GlaxoSmithKline | Blenrep | $20 | 1 payment
|
| Ipsen Biopharmaceuticals | Somatuline Depot | $20 | 1 payment
|
| Acrotech Biopharma | Beleodaq | $16 | 1 payment
|
| Organon | None | $15 | 1 payment
|
| Secura Bio | Farydak | $15 | 1 payment
|
| Novocure | Optune | $13 | 1 payment
|
| Gilead Sciences | None | $12 | 1 payment
|
2020: $4,903
| Puma Biotechnology | Nerlynx | $1,119 | 6 payments
|
| E.R. Squibb & Sons L.L.C. | Opdivo | $304 | 17 payments
|
| Merck Sharp & Dohme | Keytruda | $280 | 14 payments
|
| Amgen | Kanjinti | $244 | 9 payments
|
| AstraZeneca Pharmaceuticals LP | Lynparza | $235 | 12 payments
|
| Genzyme | Sarclisa | $229 | 11 payments
|
| Genentech USA | Venclexta | $202 | 12 payments
|
| Karyopharm Therapeutics | Xpovio | $165 | 5 payments
|
| Pfizer | Inlyta | $158 | 10 payments
|
| Seagen | Tukysa | $138 | 6 payments
|
| Incyte | Jakafi | $109 | 5 payments
|
| Teva Pharmaceuticals USA | Bendeka | $107 | 5 payments
|
| Exelixis | Cabometyx | $106 | 4 payments
|
| Novartis Pharmaceuticals | Kisqali | $91 | 4 payments
|
| Alexion Pharmaceuticals | Ultomiris | $91 | 4 payments
|
| Bayer HealthCare Pharmaceuticals | Stivarga | $84 | 4 payments
|
| Eisai | Lenvima | $79 | 4 payments
|
| Lexicon Pharmaceuticals | Xermelo | $70 | 3 payments
|
| Astellas Pharma US | Padcev | $66 | 3 payments
|
| Regeneron Healthcare Solutions | Libtayo | $63 | 3 payments
|
| GlaxoSmithKline | Zejula | $62 | 2 payments
|
| Celgene | Inrebic | $60 | 3 payments
|
| Pharmacyclics LLC An AbbVie | Imbruvica | $52 | 3 payments
|
| Janssen Biotech | Darzalex | $51 | 2 payments
|
| Taiho Oncology | Inqovi | $49 | 2 payments
|
| Boehringer Ingelheim Pharmaceuticals | Gilotrif | $48 | 3 payments
|
| Dova Pharmaceuticals | Doptelet | $45 | 2 payments
|
| Clovis Oncology | Rubraca | $44 | 2 payments
|
| TOLMAR Pharmaceuticals | Eligard | $43 | 2 payments
|
| Rigel Pharmaceuticals | Tavalisse | $35 | 2 payments
|
| Secura Bio | Farydak | $34 | 2 payments
|
| EMD Serono | Bavencio | $29 | 1 payment
|
| Takeda Pharmaceuticals U.S.A. | Alunbrig | $27 | 1 payment
|
| Coherus Biosciences | Udenyca | $27 | 1 payment
|
| Kyowa Kirin | Poteligeo | $26 | 1 payment
|
| Integra LifeSciences | Bilayer Wound Matrix (Bwm) | $25 | 1 payment
|
| AbbVie | Venclexta | $25 | 1 payment
|
| AMAG Pharmaceuticals | Feraheme | $24 | 1 payment
|
| Blueprint Medicines | Gavreto | $24 | 1 payment
|
| Lilly USA | Alimta | $24 | 1 payment
|
| Acceleron Pharma | Reblozyl | $24 | 1 payment
|
| TerSera Therapeutics | Quzyttir | $21 | 1 payment
|
| Agios Pharmaceuticals | Tibsovo | $21 | 1 payment
|
| Epizyme | Tazverik | $21 | 1 payment
|
| Foundation Medicine | Foundationone | $20 | 1 payment
|
| Kite Pharma | None | $20 | 1 payment
|
| Array Biopharma | Braftovi | $20 | 1 payment
|
| Sirtex Medical | Sir-Spheres Microspheres | $19 | 1 payment
|
| BeiGene USA | Brukinsa | $19 | 1 payment
|
| EUSA Pharma (US) | Sylvant | $14 | 1 payment
|
| Daiichi Sankyo | Enhertu | $11 | 1 payment
|
2019: $5,154
| Genentech USA | Tecentriq | $443 | 29 payments
|
| Amgen | Kyprolis | $420 | 12 payments
|
| E.R. Squibb & Sons L.L.C. | Opdivo | $408 | 31 payments
|
| Astellas Pharma US | Xtandi | $318 | 8 payments
|
| Pfizer | Ibrance | $316 | 24 payments
|
| Novartis Pharmaceuticals | Mekinist | $280 | 14 payments
|
| AstraZeneca Pharmaceuticals LP | Lynparza | $270 | 14 payments
|
| Genzyme | Jevtana | $255 | 14 payments
|
| Merck Sharp & Dohme | Keytruda | $243 | 11 payments
|
| Bayer HealthCare Pharmaceuticals | Stivarga | $239 | 6 payments
|
| Alexion Pharmaceuticals | Ultomiris | $188 | 6 payments
|
| Janssen Biotech | Darzalex | $188 | 6 payments
|
| Celgene | Abraxane | $147 | 6 payments
|
| Lilly USA | Alimta | $141 | 9 payments
|
| Takeda Pharmaceuticals U.S.A. | Ninlaro | $133 | 5 payments
|
| Boehringer Ingelheim Pharmaceuticals | Gilotrif | $121 | 5 payments
|
| Tesaro | Zejula | $119 | 7 payments
|
| Teva Pharmaceuticals USA | Bendeka | $96 | 5 payments
|
| Incyte | Jakafi | $95 | 5 payments
|
| Puma Biotechnology | Nerlynx | $87 | 4 payments
|
| Aurobindo Pharma USA | Folotyn | $76 | 1 payment
|
| EMD Serono | Bavencio | $74 | 3 payments
|
| Clovis Oncology | Rubraca | $64 | 3 payments
|
| Verastem | Copiktra | $57 | 3 payments
|
| Gilead Sciences | None | $56 | 3 payments
|
| Rigel Pharmaceuticals | Tavalisse | $51 | 3 payments
|
| Kyowa Kirin | Sancuso | $47 | 2 payments
|
| Novocure | Oncology | $30 | 2 payments
|
| Pharmacyclics LLC An AbbVie | Imbruvica | $24 | 1 payment
|
| Dova Pharmaceuticals | Doptelet | $24 | 1 payment
|
| Daiichi Sankyo | Injectafer | $24 | 1 payment
|
| Sanofi-Aventis U.S. | Elitek | $23 | 1 payment
|
| Heron Therapeutics | Sustol | $22 | 1 payment
|
| Spectrum Pharmaceuticals | Folotyn | $21 | 1 payment
|
| Janssen Pharmaceuticals | Xarelto | $18 | 3 payments
|
| AbbVie | Venclexta | $14 | 1 payment
|
| Secura Bio | Farydak | $12 | 1 payment
|
| Helsinn Therapeutics (U.S.) | Akynzeo | $12 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Novartis Pharmaceuticals Corporation · A Randomized Double Blind Placebo Controlled Study of Lee011 in Combination With Letrozole for the Treatment of Postmenopausal Women With Hormone Receptor Positive Her2 Negative Advanced Breast Cancer Who Received No Prior Hormonal Therapy for Advanced Disease · 2021 | Their institution | $21,099 |
| Novartis Pharmaceuticals Corporation · A Randomized Double Blind Placebo Controlled Study of Lee011 in Combination With Letrozole for the Treatment of Postmenopausal Women With Hormone Receptor Positive Her2 Negative Advanced Breast Cancer Who Received No Prior Hormonal Therapy for Advanced Di · 2022 | Their institution | $5,500 |
| Secura Bio, Inc. · Clbh589d2222 · 2022 | Their institution | $2,500 |
| Novartis Pharmaceuticals Corporation · A Phase II Multicenter Three Cohort Study of Oral Cmet Inhibitor Inc280 in Adult Patients With Egfr Wild Type Wt Advanced Non Small Cell Lung Cancer Nsclc Who Have Received One Or Two Prior Lines of Systemic Therapy Foradvanced Metastatic Disease · 2019 | Their institution | $1,090 |
| Novartis Pharmaceuticals Corporation · A Phase II Multicenter Three Cohort Study of Oral Cmet Inhibitor Inc280 in Adult Patients With Egfr Wild Type Wt Advanced Non Small Cell Lung Cancer Nsclc Who Have Received One Or Two Prior Lines of Systemic Therapy Foradvanced Metastatic Disease · 2020 | Their institution | $1,080 |
| Novartis Pharmaceuticals Corporation · A Randomized Double Blind Placebo Controlled Study of Lee011 in Combination With Letrozole for the Treatment of Postmenopausal Women With Hormone Receptor Positive Her2 Negative Advanced Breast Cancer Who Received No Prior Hormonal Therapy for Advanced Di · 2020 | Their institution | $846 |
| Novartis Pharmaceuticals Corporation · A Multicenter Randomized Open Label Phase 2 Study Evaluating the Safety and Efficacy of Three Different Regimens of Oral Panobinostat in Combination With Subcutaneous Bortezomib and Oral Dexamethasone in Patients With Relapsed Or Relapsed Refractory Multi · 2019 | Their institution | $800 |
| Novartis Pharmaceuticals Corporation · A Randomized Double Blind Placebo Controlled Study of Lee011 in Combination With Letrozole for the Treatment of Postmenopausal Women With Hormone Receptor Positive Her2 Negative Advanced Breast Cancer Who Received No Prior Hormonal Therapy for Advanced Di · 2019 | Their institution | $608 |
| Novartis Pharmaceuticals Corporation · A Phase II Multicenter Three Cohort Study of Oral Cmet Inhibitor Inc280 in Adult Patients With Egfr Wild Type Wt Advanced Non Small Cell Lung Cancer Nsclc Who Have Received One Or Two Prior Lines of Systemic Therapy Foradvanced Metastatic Disease · 2021 | Their institution | $458 |
| Novartis Pharmaceuticals Corporation · A Multicenter Randomized Open Label Phase 2 Study Evaluating the Safety and Efficacy of Three Different Regimens of Oral Panobinostat in Combination With Subcutaneous Bortezomib and Oral Dexamethasone in Patients With Relapsed Or Relapsed Refractory Multi · 2020 | Their institution | $225 |
| Novartis Pharmaceuticals Corporation · A Phase II Multicenter Three Cohort Study of Oral Cmet Inhibitor Inc280 in Adult Patients With Egfr Wild Type Wt Advanced Non Small Cell Lung Cancer Nsclc Who Have Received One Or Two Prior Lines of Systemic Therapy Foradvanced Metastatic Disease · 2022 | Their institution | $140 |
Checkups this office reported
8 measures · 2023
Medicare asked this office to report how often certain checkups happened in 2023. This is not a grade for the doctor. A specialist’s patients may not need every screening.
- Medicare’s overall office score
- 100.0 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
| Advance care plan on fileOlder patients with an advance care plan or a documented conversation about one | 94%That's most of the people this applied to. | 1,073 |
| Asked about smokingPatients asked about tobacco, with help to quit if they smoke | 98%That's most of the people this applied to. | 1,500 |
| Breast cancer screeningEligible women who got a mammogram | 0%That's few of the people this applied to. | 680 |
| Colon cancer screeningEligible adults who got a colon cancer test | 2%That's few of the people this applied to. | 1,077 |
| Depression screeningPatients screened for depression, with a follow-up plan if needed | 83%That's most of the people this applied to. | 1,726 |
| Medications listed in the chartVisits where the current medication list was documented | 79%That's most of the people this applied to. | 8,055 |
| Oncology: Medical and Radiation - Pain Intensity QuantifiedAs Medicare defines this measure | 75% | 2,641 |
| Oncology: Medical and Radiation - Plan of Care for PainAs Medicare defines this measure | 22% | 283 |
What the office says it does
Boxes the office ticked on its Medicare worksheet for 2023. Nobody checks these.
- Provide 24/7 Access to MIPS Eligible Clinicians or Groups Who Have Real-Time Access to Patient's Medical Record
Professional record
- NPI
- 1598758062
- Licence
- CA 20A6598
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- Yes
- Taxonomy
- Federal specialty code 207RH0003X (207RH0003X)
- Mailing address
- 541 W Colorado St Ste 205, Glendale, CA, 91204
- NPI first listed
- 2005-08-30
- NPI last updated
- 2020-03-13
- NPI record certified
- 2020-03-13
This is when the NPI record was last certified, not a medical board exam.